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.Abstract of the Dissertation
Nanoparticle Enabled Enzyme Delivery for Cancer
by
Negin Mokhtari
Doctor of Philosophy in Electrical Engineering (Nano-Scale Devices and Systems)
University of California San Diego, 2017
Professor Sadik Esener, Chair
Foreign enzymes have shown great promise as therapeutic agents, owing
to their natural specificity, substrate selectivity, and validated mechanism of ac-
tion; however, since most of these enzymes have bacterial sources, they are rapidly
cleared by the immune system. Their relatively large size and delicate nature
complicates their encapsulation in most current delivery technologies, resulting in
their poor pharmacokinetics and survival through biological barriers, as well in-
efficient therapeutic effect. Thus, there is an imminent need for a platform that
protects these enzymes from the immune system and efficiently delivers them to
the target site. This dissertation examines two different nanoparticle platforms and
their applications in enzyme delivery: synthetic hollow enzyme loaded nanospheres
(SHELS) and enzyme-loaded silica-coated PLGA nanoparticles (SiLGA). The porous
silica coating on the nanoparticles will allow them to operate like nanosharkcages,
xvi
where an enzyme (the scuba diver) is trapped in the nanoparticles (the sharkcage)
and are only accessible to small molecules like their substrate (small fish), but not
bigger molecules like antibodies and blood proteins (sharks). The application of
SHELS (previously developed) is examined in the depletion of the amino acid, me-
thionine, using the enzyme, methioninase (MethSHELS). MethSHELS are clearly
superior to bare methioninase in vitro in terms of protecting the enzyme from pro-
teases and inactivation by albumin, as well as a more widespread and sustained
methionine depletion in vivo. In an attempt to develop a simpler synthesis process
using FDA approved materials, as well as to address challenges associated with
current technologies (e.g. limitation of cargo encapsulation by size and burst re-
lease of protein cargo), a new delivery platform, SiLGA, is introduced. SiLGA was
successfully synthesized and characterized its encapsulation capabilities were also
tested with multiple enzymes in vitro. SiLGA shows superior protection capability
compared to bare enzyme. SiLGA retains more than %83 of its cargo’s enzymatic
activity in the presence of protease enzymes in vitro and exhibits exceptional lo-
calization in vivo for more than 60 days. While SiLGA has shown minimal toxicity
in mice and cells, our preliminary results in enzyme prodrug therapy shows suc-
cessful and selective prodrug activation by enzyme-loaded SiLGA and cytotoxicty
against cancer cells. SiLGA is a new delivery platform and can be employed in
several different therapeutic and diagnostic applications. The inert nature of the
FDA-approved materials used to fabricate these nanoparticles, as well as their
mechanism of action, gives a high edge to the practical use of SiLGA for enzyme
delivery for cancer and other diseases.
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Chapter 1
Introduction
Although numerous efforts have been made in the area of drug discovery
for cancer treatments, the delivery of those treatments to the target site remains
a great challenge. This is not only true for cancer therapies , but for the therapies
of many other diseases. This issue has its roots in evolution, as our survival as
species was largely based upon our body’s ability to fight and clear any foreign
agents. This serves a great purpose when the foreign agents are bacteria or viruses,
however when it comes to immune clearance of therapeutic drugs or enzymes, the
fast clearance of these agents from the body becomes the main biological barrier
to achieving therapeutic effect. In addition to delivery, the systemic and non
specific toxicity of conventional therapies themselves has become a great issue to
patients and as it is often heard in a clinical setting from doctors and patients,
"sometimes the side effects of the chemotherapy drugs are worst than the cancer
itself". To overcome this non specific and systemic toxicity effect, development of
more targeted therapies is necessary. Enzymes have a natural specificity for their
substrate and can be used as a therapeutic agent or be used in combination with
conventional chemotherapy drugs. However most of the enzyme therapies utilize
foreign enzymes which are mostly derived from bacterial sources giving them low
half lives and poor pharmacokinetics in the body. In most methods, the enzyme
or drug is either modified directly (like PEGylation) which not only will cause
partial loss of enzymatic activity but also ultimately is met with limited success of
protecting the enzyme from immune clearance, or by encapsulation of the payload
1
2inside or on the surface of different types of nanoparticles like polymers. However
specially in the case of payloads like enzymes, due to the relatively large size of some
enzymes and their delicate nature, encapsulation of enzymes inside nanoparticles
has had limited success. To address these issues, this dissertation will go over
two different kind of nanoparticle delivery platforms. These nanoparticles will
operate like nanosharkcages where a scuba diver ( the enzyme) is trapped in the
nanoparticles ( the sharkcage). The bars of the shark cage are big enough for
small fish ( substrate and products) to get in, but too small for the scuba diver
(enzyme) to get out and for sharks (antibodies, large serum proteins like albumin)
to reach the scuba diver, thus keeping the scuba diver safe. The porous silica
coating utilized on the surface of these nanoparticles is what gives it the shark
cage quality. In addition to the porous nature of silica, it is an excellent candidate
due to its biodegradability, bio-compatibility, low toxicity, adjustable porosity,
and thermal and mechanical stability, making it suitable for in vivo applications
[1, 2, 3, 4, 5, 6]. In comparison to other polymeric drug delivery vehicles, silica
nanoparticles are more resistant to pH, heat, mechanical stress, and degradation
by hydrolysis[6].
This dissertation will begin with an introduction to cancer, conventional
cancer therapies including an introduction to enzymes and enzyme therapies, and
the biological barriers for drug and enzyme delivery, followed by an overview of
current enzyme delivery technologies and their challenges and shortcomings.This
chapter will also briefly discuss the idea behind nanosharkcages.
Chapter 3 of this dissertation will focus on Synthetic Hollow Enzyme Loaded
Silica nanospheres (SHELS), its application in amino acid depletion of methion-
ine for cancerous tumors using the enzyme methioninase via methioninase loaded
SHELS (MethSHELS). MethSHELS will be synthesized and characterized in vivo
and in vitro and their future potential and shortcomings will be discussed.
In chapter 4 a new nanoparticle will be introduced: silica coated enzyme
loaded PLGA nanoparticles (SiLGA). Beta Lactamse will be used as a mock en-
zyme and BLA-SiLGA’s functional and structural characterization in vitro as well
as its in vivo tissue residence time in mice will be discussed.
Chapter 5 will explore SiLGA’s application for enzyme prodrug therapy pre-
3liminary results using horse radish peroxidase encapsulated SiLGA (HRP-SiLGA)
and indoleacetic acid (IAA) as the nontoxic prodrug. Successful synthesis of cata-
lase loaded SiLGA (CAT-SiLGA) will be discussed and their potential applications
in antioxidant therapy and diagnostics will be highlighted.
The dissertation concludes by a summary of results and discussions as well
as future directions for MethSHELS and SiLGA nanoparticles.
Chapter 2
Background
2.1 Cancer
2.1.1 What is Cancer
Cells are the building blocks of the body. We have more than a hundred
million cells in our bodies.New cells are constantly made and replace the old cells,
while the old cells will go through programmed cell death (Apoptosis). This process
in our bodies is highly regulated.
Cancer develops when the body’s controlled mechanism of cell growth and
death stops working properly. This abnormal cell growth and division forms a
mass called a tumor. Some cancers like leukemia ( blood cancer) do not form solid
tumors.
Cancer is among the leading causes of death worldwide. In 2012, there
were 14 million new cases and 8.2 million cancer-related deaths worldwide and it
is projected that the number of new cancer cases will rise to 22 million within the
next two decades [7]. According to the American Cancer Society, the probabil-
ity of developing cancer during one’s lifetime is one in two men and one in three
women. For a cell to become cancerous, the cell goes through genetic changes.
The nucleus of the cell contains our DNA, that is made of genes (figure 2.1) . The
genetic information contained in the DNA is in the form of a chemical code, called
the genetic code. This code tells the cell what proteins or RNA to produce and
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5holds instructions for the cell’s life span,function, maturity, and death. Errors and
mismatches can happen on gene as the cell is dividing. These errors are called
genetic mutations. Among other things, mutations can cause a cell to undergo un-
controlled cell division and bypass checkpoints for programmed cell death and the
cells will start to grow out of control. However mutations are common in our cells
and are usually corrected and repaired. However overtime the mutation can build
up and this effected can be intensified as more abnormal cells continue their fast
growth rate and acquire mutations.Thus cancer in general is not a single mutation
but an accumulation of mutations (figure 2.2. The most prominent genetic muta-
tions in cancer are through mutations in proto-oncogenes, tumor suppressor genes,
and DNA repair genes. These changes are sometimes called "drivers" of cancer [7].
A proto-oncogene is a normal gene that codes for proteins that helps to regulate
normal cell growth and differentiation. Once mutations or over expression occurs
in the proto-oncogene it becomes an oncogenes, allowing cells to grow and survive
when they should not. Tumor suppressor genes are involved in cell control of cell
division and once altered can result uncontrolled cell division. The DNA repair
genes are involved in repairing damaged DNA. Mutations in these genes can cause
a spiral effect of mutation in additional genes [7].
Mutations can be caused by random errors, but the majority of cancers
(%90-95) are caused by environmental factors such as tobacco (%25-30), diet and
obesity (%30-35), infections (%15-20), radiation (both ionizing and non-ionizing,
up to %10), stress, lack of physical activity and environmental pollutants [8]. And
some people can inherit genetic mutations that make them more likely to develop
a cancer (%5-10).
Not all type of tissue abnormalities leads to cancer. Some could develop to
cancer, but others are just monitored and do not develop to cancer ( figure 2.3).
For instance, cells can grow fast within a tissue due to chronic irritation or other
factors but look normal under the microscope (hyperplasia). Disyplasia is a more
serious forms of hyperplasia where cells look abnormal under microscope but are
not cancerous. When these abnormal cells are containced within the tissue they
are called carcinoma in situ and if detected,are usually treated. Carcinoma in situ
is sometimes considered as stage zero cancer. Even so, many carcinoma in situ will
6Figure 2.1: The cell and DNA [7]
not develop to cancer.
As the cancer cells continue its abnormal growth, a tumor is formed. A
tumor can be benign (not cancerous) or malignant (cancerous). Benign tumors
usually grow quite slowly and don’t spread to other parts of the body (they don’t
metastasize). If these cells break through the basement membrane of the tissue
the cancer is considered invasive. As the tumor gets bigger, its need for nutri-
ents increases. This leads to tumors building their own blood supply from existing
blood supplies (angiogenisis). Once this step happens, the tumor growth rate picks
up. This is the reason why many drugs target angiogenesis ( like bevacizumab
(Avastin) that stops angiogenesis by blocking vascular endothelial growth factor
(VEGF) from attaching to VEGF receptors that line the blood vessels).
7Figure 2.2: Cancer and mutations from http://kintalk.org/genetics-101/.
2.1.2 Metastasis
The original location of the tumor is referred to as the primary cancer.
When cancer cells have the ability to spread to other places in the body, they
are referred to as metastatic cancer and the process that they spread throughout
the body is called metastasis ( figure 2.4). As we will see later, cancers are named
after the original tumor side, not the metastasis site. The metastasized tumor cells
usually have similar traits as the primary tumor. Once the tumor cells start to
metastasize, it becomes very difficult to treat cancer. Thus one of the main ways
of tackling cancer is through early detection, where cancer can be detected at its
early stages, specifically before metastasis.
The events leading to cell metastasis is commonly referred to as the invasion-
metastasis cascade.The epithelial cells in primary tumors metastasis is as followed:
(1) local invasion to neighbouring tissue (2) intravasate into blood vessels, (3)
surviving circulation (4) arrest at distant organ sites, (5) extravasate into distant
tissues, (6) adjust and survive the new microenvirnment and form micrometastases
(7) Re initiate growth and proliferation (metastatic colonization [9](Figure 2.5)
8Figure 2.3: Normal and abnormalities in cell growth [7]
2.1.3 Types of Cancer
The heterogeneity of tumors as well as the individuality of each person’s
genetic mutations in cancer, is why cancer is no longer thought of as one disease,
but a subtype of more than 100 diseases.
Cancers are usually named after after the organ where it originated or the type of
cell the formed the cancer cells. Some of the main types of cancers are mentioned
below [7]:
Carcinomas are cancer of the epithelial cells and are the most common
type of cancer. Adenocarcinomas are cancer of the epithelial cells that produce
fluids (like breast, prostate), squamous cell carcinoma originates in squamous cells,
basal cell carcinoma originates in the basal layer of the epidermis, and transitional
cell carcinoma originates transitional epithelium.
Sarcomas are cancers the originate in the bone and soft tissues such as
muscle, fat, blood vessels, lymph vessels,nerves and fibrous tissue (like tendons and
ligaments).
Blood cancer, are cancers that originate in the blood cells. The most
common blood cancers are multiple myeloma, leukemia and lymphoma. Multiple
myeloma is a cancer that originates in a type of white blood cells known as plasma
9Figure 2.4: Cancer metastasis [9]
cells that can accumulate and overcrowd the bone marrow.
Leukemia originates in immature blood cells that overcrowd the bone mar-
row and normal blood cells. Leukemias are grouped based on how fast the disease
grows ( chronic and acute) as well as the blood cell it originates in (lymphoblastic
or myeloid).
Lymphoma (or non-hodgkin lymphoma) is a cancer that begins in lym-
phocytes (T cells or B cells). Hodgkin lymphoma, is marked by the presence of an
abnormal lymphocyte called the Reed-Sternberg cell (derived from B lymphocyte).
About %90 of lymphomas are non-Hodgkin lymphomas
Melanoma is cancer that begins in cells that become melanocytes (cells
that make melanin).
Germ cell tumors are tumors that originate in the germ cells.
Brain and Spinal Cord Tumors, are cancers that originates in the cells
of the brain and spinal cord like astrocytic tumors that originate in astrocytes.
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Figure 2.5: Metastasis of tumor cells. Tumor cells initially leave the primary
cite and locally invade and intravesate through neighbouring tissue, transport and
survive circulation, arrest at a distant tissue and extravegate, form micrometastasis
and later metastatic colonization [9].
Endocrine tumor originate in hormone releasing cells. The tumor cells
developed are able to release hormones as well. A neuroendocrine tumor originate
in cells that are a combination of hormone-producing endocrine cells and nerve
cells.Carcinoid tumors are a type of neuroendocrine tumor. They are slow-growing
tumors that are usually found in the gastrointestinal system
2.2 Treatments for Cancer
2.2.1 Conventional Therapies for Cancer
There are many different approaches to treat and kill cancerous tumors.
The most conventional ways are : surgical removal of the tumor, radiation therapy
where high doses of radiation is used to shrink or kill tumor cells and chemotherapy
where chemical drugs are used to treat tumors. Hormone therapy can also be used
in cancers like breast and prostate ( where hormones promote cancer growth)
by blocking the body’s ability to produce hormones or interfere with hormonal
functions.There are many newer areas for cancer therapies such as immune therapy
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that uses the bodies own immune system to recognize and destroy cancer cells.
2.2.2 Limitation of Conventional Cancer Therapies
While many of these treatments have been the standard of care for a very
long time, they have had limited success in the past [10]. Many tumors are
non-operable and even after operation require additional adjuvant chemotherapy.
Chemotherapy itself is limited by several drawbacks, including systemic toxicity,
lack of specificity and selectivity for cancer cells vs normal cells, immune clearance
and low circulation half lives, insufficient drug concentrations in tumors, solubility
and stability in vivo (specially for hydrophobic drugs),inability to pass through
the blood brain barrier (BBB) for applications in brain tumors, development of
major and unwanted side effect and development of drug resistance due to repeated
administration and dosing [11, 12, 13, 14, 15, 16]
2.3 Enzyme Therapy for Cancer
Enzymes have been utilized in many different therapies. For instance in
enzyme pro-drug therapy for tumors, an inactive and non toxic form of a drug
(pro-drug) is systemically administered and activated to its toxic and active form
by an enzyme at the tumor site [11, 17, 18]. Another example is depletion of amino
acids that are essential for tumors growth but their depletion does not effect normal
cells. For instance L-aspargin depletion using Asparaginase has for treatment of
childhood acute lymphoblastic leukemia [19, 20, 21, 22],methionine depletion using
Methioninase e for tumors with p16 deletions that also affect methylthioadenosine
phosphorylase (MTAP) [23, 24] and arginine depletion using arginine deiminase
for treatment for hepatocellular carcinomas and melanomas and prostate cancer
tumors [25, 26, 27].
The natural specificity and selectivity that enzymes have for their substrates
makes them a highly specific tool for targeted therapy. More over the high growth
rate of cancer cells and their increase need for amino acids, provides a unique
opportunity to deplete amino acids using enzymes.
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2.3.1 Enzymes
To gain a better understanding of enzyme therapy for cancer and its ad-
vantages and challenges, a deeper knowledge of enzyme-substrate interaction is
needed. Enzymes are proteins that accelerate and catalyze reactions while they
are not used in the reaction themselves. Different enzymes can be active in dif-
ferent temperatures and PH. While increased temperatures can lead to increased
enzymatic reaction rates, dramatic changes in PH, high temperature and salt con-
centration, can lead to enzyme denaturation and thus lead to enzyme inactiva-
tion. Some enzymes, like Methioninase, have cofactors. A cofactor is a nonorganic
molecule that are essential for enzymatic function. This means that if this cofactor
is sequestered from the enzyme, the enzyme will be inactivated.
When an enzyme binds to its substrate it forms an enzyme-substrate com-
plex. After the reaction is completed, the enzyme will return to its original state.
Enzymes are very specific to their substrates. In the past the enzyme-substrate
binding was though of as a lock and key model while nowadays this binding is
thought of more as an induced fit model where when the enzyme and substrate in-
teract there is a mild shift in the enzymes structure to accommodate the substrate
and have an optimum fit (figure 2.6).
Figure 2.6: Enzyme-substrate interaction (from OpenStax College, Biology, CC
BY 3.0)
One of the best known model for enzyme kinetics is described by Michaelis-
Menten kinetics. Many enzymes follow the Michaelis-Menten kinetics where the
rate of catalysis (which is defined as the number of moles of product formed per
second) increases linearly as the substrate concentration [S] is increased and then
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reaches a plateau where the active site of the enzyme is saturated with substrates
( figure 2.7. The Michaelis constant (KM) is the substrate concentration yielding
a velocity of Vmax/2 and is a measure of enzyme-substrate affinity.
Figure 2.7: A generic example of an enzyme following michaelis-menten kinetics.
In this plot of the reaction velocity (V0) changes as a function of the substrate
concentration [S]. Vmax is the maximal velocity reached by the system and the
michaelis menten constant (Km) is where the substrate concentration yields a
velocity of Vmax/2.
2.3.2 Limitations of Enzyme Therapy
Recombinant enzymes have a foreign nature, and this fact by itself results in
rapid immune clearance from the body. Hence even though recombinant enzymes
are highly specific for their substrates and have shown great promise for cancer
therapy applications, their clinical use in the past have been limited to their poor
pharmacokinetics and rapid clearance by the immune system [28, 29, 30, 16]. For
many enzymes that have cofactors this issue becomes even more challenging. Even
though methioninase showed great promise in clinical trials it was later discovered
that its cofactor (pyrodoxal phosphate) was rapidly sequestered by albumin in
the blood, causing enzyme deactivation [31, 32]. The most common attempt at
increasing enzymatic half life is the use of poly(ethylene glycol) (PEG) [33, 31, 34].
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Although increased circulation half lives and decreased clearance is observed in
this method, enzymatic activity is significantly reduced due to direct modification
of the enzyme with PEG. This method also can result in antibody generation
against PEG, weaken retention at the target site, degradation of PEG itself and
increased costs and optimization due to direct and specific enzyme modification
and ultimately might not result in complete enzyme protection [35, 36, 31].
There for there is an great need for a platform that protects the enzyme
from antibody neutralization, immune clearance and cofactor loss in vivo without
directly modifying the enzyme itself and at the same time allow substrate access
to the enzyme.
2.4 Nanoparticles are the Trojan Horse of the
War Against Cancer
Many current therapeutic agents and chemotherapy drugs are very potent
highly cyto toxic to cancer cells, however the main issue is that they are non
specific. Meaning that they have the same effect and toxicity to normal cells.
Thus while new drug discoveries are necessary, safe and targeted delivery of these
agents is of high importance as well. Delivery is a very important issue, not only
in cancer therapeutics or diagnostics, but also in any disease or condition that
relies on availability of a therapeutic agent to a specific organ or site. For this
purpose, nanoparticles are excellent candidates. Nanoparticle delivery platforms
have shown to overcome pharmacokinetic limitations associated with conventional
drug formulations [37]. Nanoparticles are though of as the "Trojan Horse" for
cancer drug/enzyme delivery. In the historic sense of the word, the Trojan horse
was a hollow wooden horse constructed by the Greeks to gain entrance to the
city of Troy during the Trojan war. The Greeks pretended to desert the war,
while some of their soldiers were hiding inside the wooden horse. The Trojan’s
saw the horse as a defeat offering and it was taken into the city. At night the
Greek warriors emerged from the horse and opened the gates to let the Greek
army in and overtake the city. The therapeutic cargo can be delivered in the
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same manner. The goal of delivery via nanoparticles is for the nanoparticle to
act like a Trojan horse and hide the cargo from the immune system and other
barriers that might destroy the cargo and safely deliver the cargo from the site of
injection to the specific target. Depending on the therapeutic end goal, the goal
can be to stay in circulation, or delivery to the interstitial space, intracellular,
etc. Therapeutic agents as well as their delivery platforms can be administered via
different routes such oral, intravenous (IV) , intraperitoneal (IP), intramuscular
(IM), subcutaneous or direct intra tumoral injections (IT).
2.4.1 Biological Barriers for Drug Delivery
The journey of a therapeutic agent, or nanoparticle containing the thera-
peutic agent to their target side is indeed a long one. Even though nanoparticles do
offer protection for their cargo, they themselves must overcome different obstacles
to reach their target. Thus nanoparticle platforms need to be designed in such a
way to maximize their chances of overcoming or bypassing these barriers and allow
for achievement of the desired therapeutic effect. Of course there are scenarios in
diseases when one can take advantage of the altered physiology resulted by the
disease to improve delivery to the disease site, such as the Enhanced Permeation
and Retention (EPR) effect.Cancer cells have increased need for nutrition due to
their fast rate of growth thus they will build their own blood supply from existing
blood supplies (angiogenisis). Since this process is done very fast, the tumors are
known to have "leaky vasculature", hence the enhanced permeation. In addition to
this, tumor tissues usually lack effective lymphatic drainage, hence the enhanced
retention effect. Nanoparticles can exploit this effect to accumulate more in the
tumor tissue compared to the normal tissues ( also called passive targeting)[38].
An example is Doxorubicin, a very well known and potent chemotherapy drugs,
limited by its major cardiotoxcity. The FDA approved liposomal doxorubicin and
Pegylated liposomal doxorubicin (doxil), is nowadays widely used in the clinic and
has shown reduced cardiotoxicty compared to patients who use conventional dox-
orubicin [39]. Even though these improved results have been shown with these
delivery platforms compared to the conventional form of the drugs, the results
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are still not optimum and overcoming biological barriers is still a great challenge
for many forms of delivery vehicles. It is important to bare in mind the route
of administration and the therapeutic end goal can significantly alter the biolog-
ical barrier that the nanoparticles will go through. For instance upon systemic
injection of nanoparticles, they will encounter opsonization and formation of the
protein corona. Upon administration of the nanoparticles, biological molecules
such as plasma proteins like serum albumin, lipids, apolipoproteins, complement
components and immunoglobulins will adsorb to the surface of the nanoparticles,
this is known as the protein corona [40, 41, 37]. The biomolecules with higher affin-
ity will have a tighter bound to the nanoparticles will form the hard corona while
the ones with lower affinity and looser bounds will form the soft corona (figure
2.8 from [42]) the composition of the protein corona is unique to each nanopar-
ticle and is a function of the nanoparticle properties such as size, surface charge,
shape, curvature, composition, surface functional groups, hydrophobicity as well as
the physiological environment that the nanoparticle is exposed to such as blood,
interstitial fluid, intracellular environment as well as the nanoparticles duration
of exposure to those environments [40]. Moreover, the composition of the corona
changes according to the disease status and it could differ for each person [43, 44]
Upon opsonization and formation of the protein corona, the nanoparticles
become recognizable and are taken up by the reticuloendothelial system (RES).
The RES system is a part of the immune system and is made of phagocytic cells
primarily monocytes and macrophages accumulate in lymph nodes,spleen, liver and
tissue resident histiocytes. Nanoparticles, particularly liposomes , are very prone to
serum mediated opsonization and recognition by the phagocytes of the RES [45].
This uptake can results in non specific distribution where high accumulation of
nanoparticles can be seen in organs, such as the spleen and the liver.There are many
strategies that are used to camouflage the nanoparticles to prevent or decrease
opsonization. The most known way is by PEGylation, where nanoparticles have
poly ethelyn glycol as a functional group on their surface. PEG will attract water
molecules and create a hydration layer around the nanoparticle [46, 47].However,
the PEG effect is transient, so eventual opsonization and macrophage clearance
still occurs [48]. Attachment of CD 47 peptides (’self’ peptides) [49], coating
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Figure 2.8: Protein corona formation on the surface of nanoparticles. Biomolecules
with high affinity are tightly bound and form the hard cornoa (green) and
biomolecules with lower affinity form are looslet and reversibly bound and form
the soft corona (red).From [42].
nanoparticles with red blood cell membranes [50] and leukocytes [51] has also been
proven to be an effective strategy [37].
For extravesation purposes, margination to the vascular wall is also an
important factor. Association with the vessel wall can increase chances of passive
(EPR effect) as well as in and active targeting where receptor-ligand binding is
essential. Particle size and shape have a great effect on margination dynamic
to the vascular walls [37]. Smaller and spherical nanoparticles tend to stay in
the cell free layer of blood that is far from the endothelial layer where they can
extravesate [52, 53, 37] while non spehrical and discoidal particles have shown
better margination to the vessel walls [54, 52].
The high intratumoral pressure presents another substantial biological bar-
rier for nanoparticles before they can accumulate at the tumor site. This high
intratumoral pressure stems from poor lymphatic drainage in cancer tumors, dense
extracellular matrix, interstitial fibrosis and compression from multiplying tumor
cells all which result in elevated interstitial fluid pressures in tumors [37, 55].
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If the theraputic goal is intracellular delivery of a theraputic agent, there
are additional barriers that the nanoparticle must overcome. Cellular uptake
also known as endocytosis can be divided into : Phagocytosis, macropinocyto-
sis, caveolae mediated endocytosis and receptor-mediated (or clatherin mediated)
endocytosis and clathrin-independent and caveolin-independent endocytosis (figure
2.9). Large particles are mainly engulfed by professional phagocytotic cells such as
macrophages, neutrophils, or dendritic cells through phagocytosis or "cell eating"
and go on to form an internal phagosome. Particles in the size range of 0.5âĂŞ5 um
in diameter are taken up by non specific macropinocytosis which occur in almost
all cell types. Smaller nanoparticles can be internalized through caveolar-mediated
endocytosis ( 60nm ), clathrin-mediated endocytosis (Up to 100-150 nm ) in which
cargo is deposited in small endocytic vesicles (usual diameter <100 nm ) that fuse
with early endosomes, and clathrin-independent and caveolin-independent endo-
cytosis ( 90nm ) [56, 57, 58, 59]. Nanoparticle uptake for most non specialized
cells is through clathrin-mediated endocytosis [60]. In phagocytosis and clatherin
mediated endocytosis, the phagosome or endosome formed after engulfing the par-
ticles will ultimately fuse with the acidic lysosome where most nanoparticles can be
degraded , but could be detrimental for delivery of genetic material. On the other
hand caveolae-mediated endocytosis results in the formation of caveolae that pinch
off from the membrane and are fused with caveosomes that have neutral PH and
have been shown to bypass lysosomes [37, 61, 62]. Coating the nanoparticles with
ligands such as folic acid, albumin and cholesterol have been shown to facilitate
uptake through caveolin-mediated endocytosis, whereas ligands for glycoreceptors
promote clathrin-mediated endocytosis [37, 63]. Using or coating nanoparticles
with cationic polymers, such as poly(l-lysine) (PLL), have been shown to facilitate
endosomal escape through interaction of the cationic charge of the polymer with
the outer negatively charged surface of the endosome, resulting in membrane flip-
ping and destabilization (also known as the ’flip-flop’ mechanism)[64, 37]
Upon successful internalization through cell, and achieving initial thera-
peutic effect, drug resistance is another major challenge of of conventional drugs,
as well as drug delivery. Multidrug resistance (MDR), either intrinsic or acquired
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Figure 2.9: Large particles are internalized by phagocytosis (a). particles >1
µmcan be internalized via non specific macropinocytosis (b). Smaller nanoparti-
cles can be internalized through caveolar-mediated endocytosis ( 60 nm , yellow
rods) (c), clathrin-mediated endocytosis ( 120nm , blue starts) (d) and clathrin-
independent and caveolin-independent endocytosis ( 90nm , red starts) (e) From
[48]
from prolonged exposure to a certain therapy, results in the eﬄux of the drugs
from cells, this will lower the intracellular concentration of the drug and result in
an incomplete therapeutic impact [37]. However using nanoparticles can alleviate
the severity of the drug resistance compared to conventional administration of the
drugs[65, 66].
Figure 2.10 from [37] summerizes the biological barriers that was mentioned
above.
An important factor to have in mind is that not all therapies need intracellular
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Figure 2.10: Biological Barriers for an intravenous injection of drug encapsulated
nanoparticle starting with opsonization and RES uptake, unspecific distribution
of the drugs in organs like spleen and kidneys,hemorheological/blood vessel flow
limitations, increased intratumoral pressure, cellular internalization, escape from
endosomal and lysosomal compartments and drug eﬄux pumps. From [37].
delivery, thus the biological barrier for each therapy, nanoparticle, and route of
administration will be different. With that being said, keeping these biological
barriers in mind is an important fact in designing an appropriate drug delivery
platform for the intended therapeutic or diagnostic impact.
2.4.2 Nanoparticle Design Criteria
Size and Bio-elimination: Nanoparticle size plays an important role in
the route by which it will be eliminated from the body. Systemically injected
particles are bioeliminated as follows:Small particles (<5nm) are cleared from the
body by the kidneys [55, 67, 48], particles that are in the nanometer range to 15
µm, accumulate mostly in the liver, the spleen, bone marrow adn the capillary
of the lungs [48, 68, 37]. However nanoparticles in the range of 100-200 nm have
been shown to be taken up by the tumor vasculator through the EPR effect and
escape filtration by liver and spleen [37]. However this effect also depends on the
permeability of the tumors, for instance poorly permeable tumors like pancreatic
tumors are less permeable and only nanoparticles <50 nm are able to accumulate
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in tumors [69, 37]. particles larger than 15 µm are removed from the circulation
by mechanical filtration in capillaries and can be lethal depending on the dose
[48, 68]. Figure 2.11 adapted from [37] shows a summary of the bioelimination of
systemically injected particles based on size.
Figure 2.11: Bioelimination of systemically injected particles. Smaller (<5nm)
particles are eliminated through the renal system, nanometer to -15um range par-
ticles accumulate in the liver, spleen and lungs. Adapted from [37]
Charge: Particles that are positively charged have been shown to be have
high cellular uptake thus a rapid clearance from circulation (lower circulation half
lives) [37]. Neutral and negatively charged particles on the other hand have shown
to have longer circulation half lives [70]. Prolonged half lives can result in improved
accumulation of the particles in the tumors.
Shape The majority of the nanoparticles that have been developed are in
spherical shape. While it is now understood that just like nanoparticle size, the
shape of the nanoparticle can also effect its in vivo distribution. Spherical nanopar-
ticles tend to remain in the center of the flow, while rod like particles tend to tumble
and drift towards the vessel walls due to variable forces and torques exerted on
them (figure 2.12 from [71]). Thus rod like particles can marginate and bind to
extravegate to the tumor through the endothelial vessel wall[71]. In addition to
margination to the vessel walls, biodistribution studies have also demonstrated
that spherical particles have increased uptake by macrophages compared to rod
like particles [71]. For example, the liver uptake of 100-nm-long nanochains with
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an aspect ratio of about 4 was significantly lower than 100nm in diameter spher-
ical nanoparticles giving the nanochains increased circulation half life and thus
increased extravasation to the tumor site [72].
Figure 2.12: Nanoparticle shape effects margination to the vessel walls. Spherical
particles tend to stay in the center while rod like particles tend to marginate to
the vessel walls. From [71]
Stability: It is very important that the synthesized nanoparticle is sta-
ble in physiological conditions. Premature degradation of the nanoparticles can
be detrimental to achieving the desired therapeutic effect as well as resulting in
unintended accumulation in healthy organs [37]
Biocompatability and minimal toxcity: Needless to say, the material
selected for the synthesis of the delivery system needs to be biocompatible with
minimal toxicity. Maximum biocompatibility is achieved when the synthesized
delivery platform interacts with the body without inducing unacceptable toxic,
immunogenic, thrombogenic, and carcinogenic responses [73]. It is important to
bare in mind that biocompatability for the most part is not an absolute term, fac-
tors such as desired therapeutic goal, target tissue, exposure half life of the delivery
system can effect the biocompatability of the said delivery system [74, 73]. Use of
FDA approved materials insures increased safety and can aid in commercialization
aspect of the delivery platform.
Baring in mind the nanoparticle criteria and the biological barriers for drugs
and drug delivery vehicles, nanoparticle design and modification should be done
with out most attention to not mainly overcome these biological barriers, but by-
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pass them when we can by incorporating novel and specific therapies such as amino
acid depletion through enzyme encapsulated nanoparticles where the nanoparticles
do not necessarily have to be delivered to the tumor, but depletion happens by the
passage of blood through the nanoparticles that can be administered I.M or I.P
[36].
2.5 Enzyme Delivery via Nanoparticles
2.5.1 Previous Work on Enzyme Delivery via Nanoparti-
cles and their Shortcomings
Using enzymes as therapeutic agents comes with the advantage of their
natural specificity for a given target, compared to general cytotoxic drugs, but
due to the relative larger size of enzymes and their delicate nature compared to
drugs, encapsulation of enzymes in nanoparticles have proven to be a challenging
task in the past. Nevertheless, encapsulation of enzymes in nanoparticles have been
widely studied in the past. For instance in single enzyme nanoparticles (SEN), each
enzyme is surrounded with a porous composite organic/inorganic network of less
than a few nanometers thick. The drawback of SENs is that it can only be applied
to limited enzymes and in addition have weak retention at the target [75, 36].
Enzymes can also be encapsulated in protecting structures. These mico or nano
strcutures could either release the enzyme such as mesoporous silica nanoparticles
[76], polymeric nanoparticles [77, 78], liposome [79] or keep the enzyme associated
with the platform such as enzyme immobilization platforms like mesa-porous silica,
polymers and polysaccharides [80, 81, 82] , enzyme encapsulation platforms such
as hollow silica, gold and polyelectrolytes nanoparticles [36, 83, 84, 85, 86].
One of the major pitfalls of methods that rely on enzyme release is pre-
mature and unspecific enzyme release in vivo [76]. In these methods although
enzymes are associated with the particles, the mere fact that they are released
makes them susceptible to immune clearance upon release and also nonspecific re-
lease at undesired sites. Polymeric particles for instance, mostly suffer from initial
burst release of the cargo [87].These methods are also limited by toxicity,stability
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issues, complicated synthesis processes and are limited by cargo size, charge and
limited by cargo choice to enzymes that have the stability to withstand synthesis
processes used to make the nanoparticles [84, 36].
2.5.2 Enzyme Delivery via Nano-sharkcages
There is a great need to develop a nanoparticle platform that while main-
taining enzymatic activity and integrity, overcomes the premature release of the
cargo in unspecific sites, and also meet the criteria of bio-compatibility, low tox-
icity, bio availability and protection of the enzyme against immune clearance in
a FDA approved, and cost effective manner with the possibility for passive and
active targeting.
Enzymes have a natural specificity for their substrates and are not used up
in reactions, by taking advantage of these natural quality of enzymes,as well as
there relatively larger size compared to drugs and substrates, one could design a
delivery platform that does not release the enzyme itself, but allows the substrate
to reach the enzyme and be converted to product, and for the product to diffuse
out. This system will operate like a nano-shark cage. The bars of the shark cage
are big enough for small fish ( substrate and products) to get in, but too small
for the scuba diver (enzyme) to get out and for sharks (antibodies, large serum
proteins like albumin) to reach the scuba diver ( figure 2.13).
This dissertation will go over two different kind of nanoparticle platforms
designed for such purpose. To give the nanoparticles the shark cage quality, they
will be coated with a porous silica layer. In addition to the porous nature of silica, it
is an excellent candidate due to its biodegradability, bio-compatibility, low toxicity,
adjustable porosity, and thermal and mechanical stability, making it suitable for
in vivo applications[1, 2, 3, 4, 5, 6].In comparison to other polymeric drug delivery
vehicles, silica nanoparticles are more resistant to pH, heat, mechanical stress,
and degradation by hydrolysis[6]. Chapter 3 of this dissertation will focus on
Synthetic Hollow Enzyme Loaded Silica nanospheres (SHELS), its application in
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Figure 2.13: Enzyme delivery via nano- shark cages. The nanoparticle will act like
shark cage, protecting the enzyme (scuba diver), and allowing small molecules like
substrates and products (small fish) to diffuse in and out of the shark cage while
larger molecules like antibodies and blood proteins (sharks) cannot diffuse in.
amino acid depletion for cancerous tumors. The third chapter will introduce a
new nanoparticle: silica coated enzyme loaded PLGA nanoparticles (SiLGA) and
its in vitro functional and structural characterization as well as its in vivo tissue
residence time. Chapter 4 will explore SiLGA’s application for enzyme prodrug
therapy in caner and its preliminary results. Chapter 5 will focus on discussion
and future directions of the nanoparticles.
Chapter 3
MethSHELS
3.1 Methionine Depletion Using SHELS
3.1.1 Background
Malignant tumors have high rate of growth and have increased need for
nutrition and also amino acids compared to normal cells. Based on this "metabolic
abnormality "of cancer cells, by depriving them of certain amino acids, one might
be able to "starve" the cancer cells to death.
Amino acid depletion using enzymes of non-human origin has been exten-
sively investigated and is a very well-known approach for cancer therapy [88, 89,
90, 91]
Therapeutic effect using this kind of therapy is mostly achieved from deep depletion
which requires high bioavailability of the enzyme.
Since most of these enzymes are recombinant, meaning they have a foreign
origin, they are rapidly cleared from the body by the immune system resulting in
poor pharmacokinetics[92, 93]. This problem has been one of the major set backs
of using foreign enzymes in enzyme therapy settings in the clinic.
Methionine is an essential amino acid, which means it can not be made in
our bodies and needs to be ingested through diet. It has been known for many
years that cancer cells have an abnormal methionine metabolism and increased
methionine dependency compared to normal cells [94, 95, 96, 97].
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In addition to these extensive literature resources, better understanding of
the methionine pathway in the body can aid with further understanding increased
methionine dependency in cancer cells. 3.1 slightly modified from [98] shows the
methionine pathway in the body.
Figure 3.1: Methionine pathway in the body[98].
Since cancer cells are dividing with a faster rate increased DNA transmethy-
lation is one of the main reasons attributed to methionine dependency in cancer
cells [94]. In addition to that, methylthioadenosine phosphorylase (MTAP), a
critical gene in the methionine salvage pathway which is located next to p16 (tu-
mor suppressor gene) on chromosome 9p21,is often co-deleted in many cancer cells
which makes them hyper sensitive to methionine depletion [94, 99, 100]. A sum-
mary of the correlation of methionine pathway with increased methionine depen-
dency is shown in Figure 3.2[94, 99, 100].
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Figure 3.2: Correlation of methionine pathway with increased methionine depen-
dency in cancer cells.
In previous studies,in a media where methionine was replaced by its imme-
diate precursor homocysteine, normal cells were able to grow but cancer cells were
not able to survive [101]. It was also shown that methionine depletion in cancer
cells can cause ,the late S/G2 phase of their cell cycle to be halted and prevent
their ability to divide [102]. This allows for methionine depletion to be used in
synergy with other drugs that are effective in this manner like Doxorubicin [98].
One of the main advantages of methionine depletion is the vast major-
ity of cancers that can be targeted for treatment. Methionine depletion has
been shown to be effective in the treatment of many different types of in vitro
cancer models like Walker-256 ( rat breast carcinoma), L1210 (mouse lymphatic
leukemia),RAG (mouse renal adenocarcinoma), TLX5 (mouse lymphoma), SK-N-
MC (human neuroblastoma),CCRF-HSB-2 (human acute lymphoblastic leukemia)
[97], as well as in vivo including neuroblastoma and breast cancer[103, 97, 104,
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31, 105, 106].
Since methionine is an essential amino acid, one of the main ways of methio-
nine restriction is through a methionine free diet. Although methionine restriction
through diet can assist with methionine depletion in vivo, it is not sufficient to
completely arrest tumor growth [107]. Moreover,prolonged methionine restriction
can have harmful effects on nutritional status and the general health of the patients
[98, 108] as well as being fatal in rats due to rapid weight loss and negative effects
on their health[108].
An alternative way to achieve methionine depletion is by the means of en-
zymes. Methionine depletion with Methioninase from Pseudomonas putida has
been extensively studies and tested in vitro and in vivo for its use in cancer as
well as in many other diseases such as heart disease and Parkinson’s disease [90,
91, 31, 105, 107, 109].
Methioninase has been cloned from Pseudomonas putida and expressed in Ecoli.
It consists of 389-441 amino acids and forms a homotetramer of four subunits of
43 KDa each (172KDa total).
Each subunit contains one Pyridoxal -5’- Phosphate (PLP) as a cofactor[102, 110].
Figure 3.3 from [110] shows the three dimensional homotetramer structure of Me-
thioninase from Pseudomonas putida (a) as well as the PLP binding site on a single
monomer (b).
Methioninase catalyzes the conversion of methionine to α -ketobutyrate,
methanethiol and ammoniac via α and γ elimination.
Pyridoxal -5’- Phosphate (PLP, also known as B6) is the cofactor of Methioninase.
As mentioned before, cofactors are essential for the enzyme to function. In the
resting state, the co-factor (PLP) is covalently bonded to the amino group of an
active site lysine[102, 31, 110]. During the reaction PLP is transferred to the sub-
strate (methionine) and is re- associated with the enzyme after the reaction[102,
110]. Figure 3.4 from [102] shows the mechanism of this reaction:
In a Pilot Phase 1 clinical trial, Methioninase was found to be safe in late
stage breast cancer patients [111]. However, sufficient methionine depletion was
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Figure 3.3: Three dimensional homotetramer structure of Methioninase from Pseu-
domonas putida (a) PLP binding site on a single monomer where the N-terminal
domain is shown in blue, the PLP-binding domain in yellow and the C-terminal
domain in red.PLP and PLP-binding Lys211 are shown in a ball and stick model
(b)[110].
only seen for a short time due to the rapid clearance of the foreign enzyme by the
immune system.
In another study, bare Methioninase triggered anaphylactic shock when it
was administered to monkeys for repeated challenge doses in consecutive days [31,
106].
In an attempt to improve enzymatic circulation half life and immune re-
action, the enzyme was later modified with Polyethylene Glycol (PEG). While
PEGylation can help with increasing enzymatic half-life, it is a challenging and
expensive task and has also been reported to reduce enzymatic activity [92, 31,
112].
Although PEGylating improved bio-availability, it was ultimately not able
to sustain systemic methionine depletion for longer periods. It was later discovered
that enzymatic activity is lost due to the rapid disassociation of PLP from the
enzyme in vivo[113]. These findings were very surprising at the time since PLP is
tightly bound to the enzyme in vitro[113].
Lys190 has been identified as the primary binding site for HSA [32, 114].
PLP was reported to be sequestered by blood proteins especially Albumin.
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Figure 3.4: Methioninase catalysis reaction with methionine by α and γ elimination
to produce α -ketobutyrate, methanethiol and ammoniac.(1) In the resting state,
the co-factor (PLP) is covalently bonded to the amino group of an active site lysine,
forming an internal aldimine. Once the substrate interacts with the enzyme’s
active site, a new Schiff base is made. (2) α- and β-hydrogens of the substrate are
transferred to PLP (3) a Phenolic group of the adjacent tyrosine residue attacks
the gamma-position of the substrate. (4) the thiol group is eliminated from the
substrate (5) α -keto acid and ammonia are released from PLP as products [102].
This finding is in alignment with Albumin’s high affinity to PLP and its role as
the main carrier of more than %95 of circulating PLP in the body [32, 114, 115].
In an attempt to recover enzymatic activity PLP was supplied at super-
physiological levels using mini-osmotic pumps in vivo and enzymatic activity was
shown to be recovered [116]. This finding further supports that prevention of PLP
loss is a very important factor for achieving adequate methionine depletion in vivo,
since PEGylation might help with increasing the enzymatic half life but is ulti-
mately not an ideal approach due to PLP disassociation in vivo.
Although these finding can aid with the activity recovery of the enzyme, clinical
translation of such method is not feasible.
Since PLP is tightly bound to the enzyme in vitro, protecting the enzyme
from PLP loss and blood protein access becomes very important in maintaining
enzymatic activity that could result in achieving deep depletion of methionine in
vivo.
As previously discussed, nanoparticles are a great vehicles for safe delivery of drugs
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and enzymes in vivo.
Nanoparticles can participate in active and passive targeting. Due to the
leaky vasculature of tumors, nanoparticles can be passively targeted using the
enhanced permeation and retention effect [117, 118]. In addition to this, the sur-
face of the nanoparticles can be functionalized with targeting ligands like vascular
endothelial growth factor(VEGF) to target VEGF receptors in the vascular en-
dothelium [119]. Moreover, since enzyme and substrate interactions are highly
specific, enzyme therapy are more advantageous in terms of targeted therapies.
With nanoparticle enzyme delivery, the enzyme could be encapsulated, en-
trapped or immobilized on the nanoparticles [120, 121]. In some cases the en-
zyme can be released by the nanoparticles [122] or it can remain active inside the
nanoparticles and allow for enzyme-substrate interaction [36].
However, enzyme delivery using nanoparticles has had limited success in
the past. This can be attributed to the relatively large size of the enzymes in
addition to their low stability due to their delicate nature.
In this chapter, by using a novel approach previously demonstrated by [36]
referred to as synthetic hollow enzyme loaded nanosphere (SHELS) , we report en-
capsulation of Methioninase in SHELS (MethSHELS) for improved bio-availability
as well as maintaining enzymatic activity. These Silica nanoparticles are able to
act as a enzyme delivery vehicle for intramuscular (IM), intratumorural (IT), intra
peritoneal(IP) or intravenous (IV) administrations.
Briefly, SHELS are made in 2 main steps. First, through a method called
nanomasking [36], amine polystyrene spheres are used as templates and are com-
bined with smaller carboxylate spheres that binds to their surface as nano-masks
by electrostatic interaction. This process is followed by the deposition of a thin
layer of silica on the nano-masked template. Here, the reaction only occurs on the
template surface where it is prevented at the locations blocked by the nano-masks.
Once silica is grown; the templates and masks are removed either by calcination
or dissolution and silica shells with large pores are formed. In the second step
Methioninase is loaded through these pores. Later the enzyme loaded nanopar-
ticles are sealed by another layer of nano porous silica resulting in MethSHELS.
This Nano porous silica layer allows small substrate such as methionine to freely
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diffuse and react with Methioninase, however the large size of antibodies and blood
proteins like albumin does not allow them access to the enzyme through the Nano
porous silica. Moreover, using this novel method eliminates the need for direct
enzyme modifications like PEGylation since the particles will be in a biocompat-
ible nanoparticle. In our previous work we have shown that asparginase loaded
SHELS are able to protect the enzyme from antibody neutralization [36]. Giving
the nanoporous nature of these nanoparticles and the inability for large molecules
to enter the particles and access the enzyme, we hypothesize that encapsulation
will protect Methioninase from albumin ( 67 KDa) and antibody access therefore
sustain enzymatic activity for longer periods of time compared to the unencapsu-
lated enzyme.
3.2 SHELS
Figure 3.5 shows a scanning electron microscopy (SEM) image of Synthetic
Hollow Mesoporous Nanospheres (SHMS and Synthetic Hollow Enzyme Loaded
nanospheres (SHELS) that have been developed in our group [36]. As it can
be seen, the meso-pores are relatively large in size (>5nm) which will be large
enough for enzymes to enter the nanoparticle through diffusion. The enzyme loaded
nanoparticles are later sealed with a nanoporous silica layer. As it can be seen,
after the sealing process the holes are covered and the enzyme is encapsulated
inside the SHELS.
In the subsequent sections enzymatic activity post encapsulation will be
verified.
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Figure 3.5: Scanning electron micrographs of A) Synthetic hollow mesoporous
nanospheres (SHMS) and B) Synthetic Hollow Enzyme Loaded nanospheres
SHELS[36].
3.3 Results and Discussions
3.3.1 Unencapsulated enzyme is not dose dependent on
PLP in vitro
To asses the bare enzyme before the encapsulation process, unencapsulated
enzyme was tested in different scenarios with its cofactor and albumin. Pyridoxal 5
phosphate (PLP) is the cofactor for Methioninase. This cofactor is essential for the
enzyme to remain active (Holoenzyme) and in case the enzyme loses its cofactor it
becomes inactive (Apoenzyme). To confirm that the enzyme is not dose dependent
on PLP in vitro, we incubated the enzyme with different concentrations of PLP
and carried out the assay as mentioned before. We were able to confirm that
Methioninase is not dose dependent on the cofactor (PLP) in vitro Figure 3.6A.
However in vivo, Human Serum Albumin (HSA) has been reported as the main
cause of enzyme inactivation[17]. Albumin sequesters the cofactor due to its high
affinity for PLP and consequently enzymatic activity is lost. To challenge the bare
enzyme in vitro, we introduced different concentrations of human serum albumin
to the assay. The bare enzyme was incubated with different concentrations of
HSA and standard assay protocol was followed to measure enzymatic activity as
mentioned before. As expected, introduction of HSA caused significant reduction
in enzymatic activity Figure 3.6B.
By confirming that PLP is tightly bound to Methioninase in vitro and
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Figure 3.6: (A) Changing PLP concentration has no effect on the bare enzyme’s
activity, confirming that bare Methioninase is not dose dependent on PLP in vitro.
(B) Although enzymatic activity was maintained at its full capacity while undis-
turbed, addition of Human Serum Albumin (HSA) had a significant effect on re-
ducing enzymatic activity.
the role of HSA in reduction of enzymatic activity, we hypothesize that Me-
thioninase could be protected from inactivation by encapsulation inside SHELS
(MethSHELS). The porous silica coating will block the access of big molecules like
antibodies and blood proteins like Albumin while allowing small molecules (like
the substrate and products) to diffuse in and out.
3.3.2 MethSHELS
Methioninase was encapsulated in the SHELS (MethSHELS) based on our
previous work [36] with minor modifications. To verify enzyme encapsulation and
activity post encapsulation, MethSHELS and free enzyme were separately incu-
bated with Proteinase-K (PK). Proteinase K is a serine protease that will cleave
any free enzyme that is not encapsulated within the SHELS or any enzyme that
is on the surface of the SHELS. The Activity measured post PK treatment will
only come from the enzymes that are encapsulated inside the SHELS. The samples
were incubated with and without PK at 370C overnight and assay was done on the
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samples post incubation as described before. As it can be seen, the bare enzyme
loses all its activity when exposed to PK Figure 3.7A while MethSHELS retain
more than %60 of their activity upon exposure to PK Figure 3.7B.
Figure 3.7: (A) Free enzyme was incubated with and without PK for overnight at
370C. Enzyme activity assay was done post incubation. While the bare enzyme
with no PK maintains %100 of its activity, bare enzyme incubated with PK loses all
its activity. (B) MethSHELS were incubated with and without PK for overnight at
370C. Activity assay was done post incubation. MethSHELS that were incubated
with PK were able to retain more than %60 of their activity.
We believe that the partial loss of activity in MethSHELS could be at-
tributed to the free and un-encapsulated enzyme that could be remaining in the
solution from incomplete washing.
3.3.3 Effect of Albumin on MetSHELS in vitro
Human serum albumin (HSA) is the most abundant plasma protein and has
a very high affinity for PLP [32]. More than %95 of the circulating PLP in the body
is bound to human serum albumin [32]. Lys190 has been identified as the primary
binding site for HSA [32, 114]. Previous studies has shown that cofactor (PLP)
loss for Methioninase in vivo can be due to the high affinity of PLP to albumin
[31]. During the catalytic reaction, PLP is sequestered by albumin and the enzyme
loses its activity due to cofactor loss. Based on our hypothesis, encapsulation of
Methioninase inside SHELS will prevent the access of blood proteins like albumin
and neutralizing antibodies in the blood due to their inability to diffuse through the
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pores of Silica because their larger size. However, substrate and products are able
to diffuse in and out and react with the enzyme due to their smaller size. Thus
the encapsulation can offer protection of the enzyme from larger molecules like
albumin in vivo thus allowing the achievement of efficient methionine depletion.
To test this hypothesis in vitro, MethSHELS were challenged by the introduction
of HSA. MethSHELS were prepared as previously mentioned and incubated as
follows: 1x10E11 MethSHELS was added to 30 mM methionine with or without
40mg/ml of HSA. The solutions were then incubated at 370C. At each time point
a sample of the solution was taken out and the proteins in the solution were
precipitated to isolate the products. We have used optical density (OD) at 320
nm as a measure of generated product. As shown in the Figure 3.8, while the
free enzyme shows a decrease in activity over time and even lower activity in the
presence of HSA, MethSHELS are able to maintain their activity throughout the
experiment.
These results in addition to our Proteinase-K study with the MethSHELS
supports our initial hypothesis stating encapsulation of enzyme within SHELS
protects the enzyme resulting in maintaining enzymatic activity in the presence of
albumin.
3.3.4 Toxicity in mice
For evaluating the toxicity of metSHELS, we used the standard preparation
of 200 nm metSHELS described above. The maximum tolerable dose was found to
be 3xE11 particles/injection/6 hours, which corresponds to around 250-300 U/kg
enzymatic activity per injection.
3.3.5 In Vivo Analysis of MethSHELS
After the encouraging results from challenging MethSHELS with PK and
HSA in vitro, we evaluated the activity of MethSHELS in vivo. For this purpose,
we compared MethSHELS with an equivalent dose of bare Methioninase. A dose
of 1.5 IU (international units) of bare Methioninase and 0.75UI MethSHELS was
injected intramuscularly into the left flank of naive mice. Samples were collected
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Figure 3.8: Effect of human serum albumin (HSA) on bare enzyme and
MethSHELS in vitro. Bare Methioninase (Free Met) and Methioninase encap-
sulated in SHELS (MethSHELS) were incubated with or without HSA (Free Met
Alb+, Free Met Alb-, MethSHELS Alb+ and MethSHELS Alb-). The bare enzyme
loses a great portion of its activity when incubated with HSA while MethSHELS
are able to maintain same level of activity with or without HSA.
at different time points and serum Methionine was measured over time (Figure ??).
We observed a deeper and more durable Methionine depletion in mice that
were injected with MethSHELS compared to bare Methioninase for up to 12 hours.
This result is, to our knowledge, the first demonstration of sustained methionine
depletion for 24 hours and suggests that encapsulation of Methioninase in SHELS
provides protection against in activation in vivo.
3.4 Conclusion
In this study, we have successfully demonstrated encapsulation of Methion-
inase with high efficiency. We have challenged the encapsulated enzyme with Pro-
teinase K and have shown MethSHELS maintain more than %60 of their activity.
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Figure 3.9: In vivo depletion of methionine by IM injection of MethSHELS and
bare Methioninase in naive mice. A dose of 1.5 IU of bare Methioninase and 0.75
UI MethSHELS were injected intramuscularly into the left flank of naive mice.
Serum Methionine was measured over time. Error bars represent the standard
deviation of at least three replicate experiments.
We believe that the limited loss of activity is due to the free and un-encapsulated
enzyme that could be remaining in the solution from washing. We have also ad-
dress one of the greatest challenges associated with Methioninase, which is enzyme
in activation in the presence of blood proteins like albumin. Previous studies have
shown the key role of human serum albumin (HSA) in sequestering PLP from
Methioninase[17] during the catalytic reaction that has been attributed to albu-
min’s naturally high affinity for PLP. We were able to successfully demonstrate our
key hypothesis stating that encapsulation of Methioninase within nanoparticles im-
proves the stability of the enzyme by protecting it from inactivation in the presence
of human serum albumin. Moreover, we have shown a more durable and deeper
depletion of IM injected encapsulated Methioninase (MethSHELS) compared to
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bare (unencapsulated) Methioninase for up to 12 hours.
For future directions, we believe further optimization of the loading and
dosing of SHELS should greatly improve the results. Despite promising results
for IM injection of MethSHELS in mice, we believe that IV administration of
MethSHELS is a more realistic approach for clinical applications. According to
our calculations, after a single injection with SHELS the volume coverage is no
more than a few cm3, so in order to populate a muscle volume as large as 1000
cm3, one needs to make 300 injections to the patient which is not feasible, hence
for future application, we would choose IV as the route of administration (figure
3.10)
Figure 3.10: Theoritical calculation for SHELS injection volume and muscle volume
In addition to this, while Methioninase has a validated mechanism of action
and effects many different cancers, it is not commercially available, thus obtaining
a high quality enzyme is very expensive and challenging. Moreover, in terms of the
nanoparticles themselves, moving to a more simple synthesis process that achieves
complete and efficient enzyme encapsulation and is not limited by enzyme size,
as well as synthesizing the nanoparticles such that it is more inline with FDA
approved material, will greatly ease the path to commercialization.
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3.5 Methods
3.5.1 Nanoparticle Synthesis and Enzyme Loading
Nanoparticles (SHELS) were prepared based on [35] with minor modifica-
tions. Preparation of Synthetic Hollow Mesoporous Nanospheres (SHMS): 50 µl of
200nm Amine functionalized polystyrene beads (Polysciences, Inc ) were used as a
template and was mixed with 60 µl of 60nm Carboxyl-functionalized polystyrene
latex particles (Life Technologies). The mixture was shaken overnight. Then 1000
µl of anhydrous Ethanol was added to the solution, followed by the addition of
1 µl of Tetramethyl orthosilicate (Aldrich-Sigma Ltd., St. Louis, Missouri ) to
initiate the silica growth. The mixture was shaken overnight. To stop the reaction
and remove excess silica, the particles where centrifuged (10 min at 14000 rpm)
and washed 3 times with deionized water. To remove the organic compounds,
the nanoparticle solution was placed on a cover slide over a hot plate and cal-
cined overnight at 4500C. The calcined powder was transferred to a tube and re
suspended in 50 µl water and dispersed by gentle sonication.
3.5.2 Preparation of Methioninase Loaded Synthetic Hol-
low Enzyme Loaded Nanospheres (Meth-SHELS)
Methioninase was obtained from( MtiBio) and dialyzed with 10mM of PLP
(Pyridoxal 5-phosphate hydrate %98, Sigma-Aldrich) in 1X phosphate buffered
saline (1XPBS) using a 10 KDa dialysis filter (Slide-A-Lyzer) MINI Dialysis De-
vice, 10K MWCO, Thermofisher Scientific) at 40C. The solution was changed at
1 hour, 3 hours, and overnight. To prepare the particles for encapsulation, the
SHMS solution was centrifuged and the supernatant was taken out. The dialyzed
enzyme was added to SHMS pellet and incubated overnight while shaking at 40C.
Later 500C µl of % 0.1 poly-L-lysine (Poly-L-lysine hydrobromide, mol wt>300,000,
lyophilized powder, Îş-irradiated, BioXtra, Sigma-Aldrich) was added to the incu-
bated solution. The solution was later diluted with 1000 µl of 1XPBS. Silicic acid
was made by adding TMOS (Tetramethyl orthosilicate (Aldrich-Sigma Ltd., St.
Louis, Missouri) to 1 mM HCl in 74:500 volume ratio and mixed for a few minutes.
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25 µl of the silicic acid solution was added to the above SHMS solution immedi-
ately after dilution and shaken for 6 hours in order to generate MethSHELS. To
wash the excess silicic acid, MethSHELS were centrifuged (10 min 14000 rpm) and
washed 3 times with 1XPBS.
3.5.3 Proteinase K Treatment for loading efficiency analy-
sis
Samples were exposed to Proteinase-K (Thermo Scientific Pierce Proteinase
K) enzyme overnight at a concentration of 0.1 mg/ml in 1X phosphate buffered
saline (PBS) solution at 370C.
3.5.4 Enzyme and Nanoparticle activity assay
The activity assay of Methioninase was done as follows: Solution prepa-
ration: A substrate solution of 30mM of L-methionine (DL-Methionine >%99,
Sigma-Aldrich) was made in 1XPBS as substrate solution. 25 µl of MethSHELS
was added to 975 µl of substrate solution. As controls, bare enzyme with matching
activity or a background solution where nanoparticles or bare enzyme was replaced
with 1XPBS was added to the substrate solution. Solutions were incubated at 370C
for different time points. The reaction was stopped by adding 125 µl of a solution of
%50 TCA(Trichloroacetic acid ACS reagent, >99.0%, Sigma-Aldrich). The resul-
tant solution was centrifuged for 10 min at 14000rpm and 250 µl of the supernatant
was added to 500 µl of 1M sodium acetate ( 3M Sodium Acetate, Corning-VWR)
and 200 µl of %0.1 of 3-Methyl-2-benzothiazolinone hydrazone hydrochloride hy-
drate (3-Methyl-2-benzothiazolinone hydrazone hydrochloride hydrate %97, Sima-
Aldrich). The solution was incubated at 500C for 30 minutes. After this the
solution was removed from the incubator and set to reach room temperature and
absorption (OD) was measured at wavelength of 320nm.Assay was carried as trip-
licates. All Absorbance intensities were measured on an Infinite00 Pro, TECAN,
Switzerland.
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3.5.5 In vitro Albumin Assay
A substrate solution containing HSA (Albumin from human serum lyophilized
powder, >%97, Sigma-Aldrich) was prepared containing final concentration of
30mM L-Methionine in 1XPBS and different Albumin concentration. For exper-
iments on bare enzyme 0.088mg of Methioninase was added to 1 ml of substrate
solution with or without HSA. In controls, Methioninase was replaced by 1XPBS.
For experiments on MethSHELS, 25 µl of MethSHELS was added to 1ml of HSA
substrate solution. As a non HSA control; 25 µl of MethSHELS was added to a
substrate solution containing only a solution of 30mM L-methionine in 1XPBS.
The solutions were incubated at 370C and stopped at different time points. At
each time point , 250 µl of sample was taken out and stopped with 32 µl TCA.
The mixture were centrifuged for 10 min and 200 µl of supernatant was added
to 200 µl of 3-Methyl-2-benzothiazolinone hydrazone hydrochloride hydrate and
500l 1M Sodium Acetate. Mixture was incubated at 500C for 30 min and OD
was measured at 320nm.The assay was carried in triplicates and bare enzyme and
MethSHELS activity was matched, with bare enzyme activity being measured as
%100 and MethSHELS activity measured accordingly. All Absorbance intensities
were measured on an Infinite00 Pro, TECAN, Switzerland.
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Chapter 4
Silica Coated Enzyme loaded
PLGA (SiLGA) Nanoparticles-
Preparation and Characterization
4.1 Background
With the goal of maintaining the nano-sharkcage effect by the porous silica
coating, alternative enzyme encapsulation routes is investigated to address the
limitations that was discussed in the previous chapter. Moving to a more simple
synthesis process that is not limited by enzyme size, as well as using more FDA
approved material can result in more efficient encapsulation and ease the path to
commercialization. With that goal in mind, Silica coated enzyme loaded PLGA
(SiLGA) nanoparticles, their successful synthesis, and structural and functional
characterization is investigated in this chapter.
4.1.1 PLGA
One of the most popular and widely used drug delivery vehicles to date is
poly(lactic-co-glycolic acid), or PLGA. PLGA has been used in sutures since the
1970’s [123]
PLGA owes its popularity to many of its unique features including: bio-compatibility,
44
45
biodegradability, potential for surface modification for targeting different cancers
and organs, and great chemical control over synthesis parameters like size and drug
release[124]. Moreover, PLGA is approved by both the Food and Drug Adminis-
tration (FDA) and the European Medicine Agency (EMA).
PLGA delivery vehicles exist in several forms, though predominantly as
particles and implants. A summary of some of the current therapies from [125] are
shown in 4.1.
Figure 4.1: Example of current therapies using PLGA[125]
Poly(lactic-co-glycolic acid) is a co-polymer of two monomers; lactic acid
and glycolic acid.
In the presence of water, the ester linkage between lactic and glycolic acids is
hydrolysed and PLGA is decomposed to its building monomers (figure4.2[124]).
Since lactic and glycolic acids are endogenous, it is easily metabolized via
the Kreb’s cycle. This feature gives PLGA minimal toxicity.
The degradation rate of PLGA depends on the molar ratio of is building
46
Figure 4.2: PLGA structure[124]
monomers. This ratio can also effect the crystallinity, hydrophilicity, and glass
transition temperature. The glass transition temperatures of PLGA co-polymers
are above the physiological temperature of 370C (around 40-60C) and decreases
with reducing molecular weight and lactic acid content; thus, PLGA possess brittle
characteristics in physiological conditions[126].
Higher lactic-to-glycolic acids ratio will result in a more hydrophobic com-
position due to higher hydrophobicity of lactic acid [127]. As such, higher glycolic
acid ratios yield in lower degradation time. An exception to this is PLGA com-
posed of a 50:50 monomer ratio that has a faster degradation rate [128].
Depending on the resulting PLGA nano/micro particle or implant, PLGA
degrades through bulk and surface diffusion as well as through bulk and surface
erosion (figure from [129]). Moreover, the degradation of the polymer to its acidic
monomers results in auto-catalysis of the degradation process itself.
The initial burst release of the cargo is related to cargo type, cargo concen-
tration, and the monomer ratio of the PLGA in use. In addition, cargo release is
also effected by the solubility of the cargo itself, as well as penetration of water
into the polymer matrix[128].
The type of cargo loaded in PLGA particles is another factor contributing
to the degradation rate of PLGA. The presence of different kinds of drugs may
change the degradation mechanism from bulk erosion to surface degradation, as
well as affect the rate of matrix degradation[130].
Cargo-to-polymer ratio is also an important factor in determining the re-
lease profile of the resulting PLGA particle, with higher drug or enzyme cargo
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Figure 4.3: Degradation mechanisms of biodegradable polymeric nanoparticles: A)
bulk erosion, B) surface erosion from [129].
content resulting in a larger initial burst release [128].
Figure from [131] shows an example of different release profiles of BSA
encapsulated PLGA nanoparticles. Depending on the formulation, different modes
of BSA release has been reported. Initial burst release as well as biphasic model
combining a moderate initial burst and a subsequent sustained release, or triphasic
model with a lag of release between both initial and sustained release phases, or
incomplete release, can all be observed. Continuous release can be seen when the
diffusion of cargo is faster than the particle degradation. The biphasic release can
be seen as an initial burst at or near the particle surface followed by a second
phase in which BSA is progressively released by diffusion. A third triphasic release
profile can also be seen when a lag release period occurs after initial burst and
until polymer degradation starts. Finally, it is possible to obtain an incomplete
protein release as a result of protein-polymer interaction or protein instability.
Regardless of the mode of release, however, initial burst release is a common
phenomena among PLGA delivery vehicles, especially with protein cargo.
4.1.2 Encapsulation of Proteins in PLGA
As it has been discussed before, unencapsulated foreign enzymes have a low
half-life in vivo. Their oral delivery for instance is limited by their susceptibility
to degradation by gastrointestinal enzymes, while other routes of systemic admin-
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Figure 4.4: Release profiles. (circle) BSA release from PLGA nanoparticles with
high initial burst release; (red dots line) biphasic model combining a moderate
initial burst and a subsequent sustained release; (blue dash line) triphasic model
with a lag of release between both initial and sustained release phases; (dash-dot
green line) incomplete release.[131]
istration is susceptible to rapid clearance by the immune system. Encapsulating
these foreign enzymes in polymeric nanoparticles, especially in PLGA nanoparti-
cles, has shown promising results in the past[122, 77, 30, 132].
Due to the hydrophilic nature of most proteins, the most common method of
protein encapsulation in PLGA particles is through double emulsion solvent evapo-
ration, or W/O/W. However, successful encapsulation of proteins even through this
method is met with challenges like protein stability, protein-polymer interaction,
and protein aggregation in the water phase[124, 133]. Achieving smaller particle
size also requires subjecting the particle solution to higher sonication powers, which
can result in loss of enzymatic activity. Due to these challenges, modified methods
need to be applied to successfully encapsulate enzymes in PLGA particles.
In an attempt to protect neurons from oxidative stress, [122] reported suc-
cessful encapsulation and release of Catalase from PLGA nanoparticles. Catalase
is an enzyme that converts hydrogen peroxide to water and oxygen, preventing
oxidative stress induced by the presence of reactive oxygen species like hydrogen
peroxide.
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In this method Catalase is encapsulated in PLGA nanoparticles using double emul-
sion solvent evaporation method. Catalase is co-encapsulated with Rat Serum
Albumin (RSA) to stabilize the enzyme in the water phase as well as protect
enzyme-polymer interactions. Dimethyl L-tartrate (DMT) is used in the oil phase
to facilitate enzyme release from the nanoparticles. Addition of the extra material
and other experimental methods, resulted in successful synthesis of Catalase en-
capsulated PLGA nanoparticles with an average size of 280 nm, a polydispersity
of 0.034, and an average zeta potential of -20.mV. These nanoparticles released
Catalase activity for a month in vitro.
Although successful encapsulation of Catalase in PLGA nanoparticles was
shown, the release mechanism of PLGA nanoparticles remains the same. Due to
the nature of the polymers, the cargo will be burst-released in vivo.
4.1.3 Shortcomings of PLGA
Even with successful encapsulation of cargo, PLGA faces substantial chal-
lenges specifically as an enzyme delivery vehicle for in vivo applications.
Protecting the foreign enzyme’s activity in vivo is essential for the enzyme
to reach its therapeutic effect.
One of the most prominent shortcomings of PLGA is the initial burst release
of the payload once PLGA is introduced in vivo. The polymeric structure of PLGA
causes a burst release profile followed by a period of slow release. This initial burst
release, specially for foreign enzymes, is a great disadvantage. Mostly this initial
burst release is an inefficient use of drug or enzyme from both therapeutic and
financial points-of-view [87]. Since enzymes are not used in the chemical reaction
that they catalyze, they retain their therapeutic effect while encapsulated. In
fact, protecting the enzyme from release will substantially decrease the immune
response against foreign enzymes. This is protection becomes crucial for enzymes
that have cofactors (like in the case of Methioninase and its cofactor PLP, metioned
in Chapter2); if such enzyme is released, it will suffer the same fate as its free
counterpart: inactivation due to immune response and cofactor loss.
Moreover the premature release of cargo from nanoparticles causes problems
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when delivery is intended for sight-specific drug or enzyme release [6].
The most important issue remains; the enzyme is going to be released into
the body, facing all of the issues that have been previously discussed. In the fol-
lowing sections, enzyme-loaded PLGA nanoparticles will be coated with a Silica
layer that, in addition to preserving all of the advantages that PLGA has to offer,
addresses the shortcomings of these nanoparticles and prevents the enzyme from
leaking from the nanoparticles.
4.2 Silica Coated Enzyme Loaded PLGA (SiLGA)
One of the biggest challenges of enzyme and drug delivery with PLGA is
the initial burst release of the cargo. With the initial burst release, in case for
cargo like drugs, the drug might not be able to reach the target tissue or cells,
leading to a loss of efficacy. Enzymatic cargo will suffer the same fate, even after
the enzyme-loaded nanoparticle reaches its phase of slow release (assuming it is
releasing to the point of having a therapeutic effect), the enzyme will be exposed
to the antibodies and blood proteins that the nanoparticle was intended to protect
it from in the first place.
Coating the surface with a layer that will prevent the enzyme from leaking
combats the burst release of the enzyme in vivo and protect the enzyme from
degradation.
The selected material should be porous enough for the enzyme’s substrate
and the resulting product to enter and exit the nanoparticles, but small enough
that enzymes are unable to escape the nanoparticles.
For this purpose, Silica was selected as the coating material for enzyme-
loaded PLGA nanoparticles.Silica is an excellent candidate due to its biodegrad-
ability, bio-compatibility,low toxicity, adjustable porosity, and thermal and me-
chanical stability, making it suitable for in vivo applications[1, 2, 3, 4, 5, 6]. In
comparison to polymeric drug delivery vehicles, Silica nanoparticles are more re-
sistant to pH, heat, mechanical stress, and degradation by hydrolysis[6].
PLGA nanoparticles encapsulating enzyme, drug, virus, nucleic acids can
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be coated with silica, a porous inorganic material. Applications of these loaded,
silica-coated PLGA (or, "SiLGA") nanoparticles are well-known in biotechnology,
nanomedicine, and enzyme/drug delivery.
In brief, a payload like an enzyme or drug is encapsulated inside poly(
lactic -co-glycolic acid) (PLGA) nanoparticles. The PLGA nanoparticles, which
encapsulate their payload, are then coated with a porous silica layer.
One simple analogy describing how this system works is to think of a SiLGA
nanoparticle like a shark cage. The scuba diver (here, the drug or enzyme) inside
the cage is too big to escape; however, small fish (here, prodrugs or substrate
molecules) can enter the cage and interact with the scuba diver. Anything big like
a shark (here, the antibodies and blood proteins) cannot get into the cage.
Since the payload is located inside the nanoparticle, the porous silica layer
hides it from the immune system. The silica coating also protects the payload itself
from in vivo inactivation, like co-factor loss, which often limits the use of certain
enzymes in vivo. Once the nanoparticle goes through endocytosis, the very acidic
conditions of the endosome degrade the particle.
4.2.1 Synthesis of Silica-Coated, Enzyme-Loaded PLGA
(SiLGA)
The first step of synthesis utilizes PLGA nanoparticles as templates - en-
capsulating the payload - onto which a porous silica layer is deposited.
In the first step of the synthesis, the enzyme is encapsulated inside PLGA
using a double emulsion solvent evaporation based on [122] with minor modifica-
tions.
In summary,first, an appropriate ratio of enzyme to Rat Serum Albumin
(RSA) is dissolved in water, yielding the initial aqueous phase (W1). RSA protects
the enzyme during the encapsulation process.
The W1 mixture is then added to the oil phase (O1), containing PLGA
(poly(lactic-co-glycolic Acid) and DMT (dimethyl L-tartrate) in of dichloromethane
(DCM), while vortex mixing; immediately afterwards, probe sonication on ice
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generates the water-oil emulsion. Here, DCM acts as an organic solvent, and
DMT serves as a plasticizer. The mixture is then added to a solution of %5 PVA
(polyvinyl alcohol) in water, which serves as the second aqueous phase (W2). PVA
acts as an emulsifier. This mixture is vortex mixed and probe sonicated on ice to
create the water-oil-water double emulsion. The organic solvent (DCM) is evapo-
rated overnight at room temperature, allowing the PLGA nanoparticles to harden.
The nanoparticle solution is then vacuum-dried for one hour, centrifuged,
and washed three times with water to remove excess PVA.
The (W/OW) nanoparticles are then coated with Silica using Silicic Acid (a
ratio of 75:500µl tetramethyoxysilane to hydrochloric acid) in 1X PBS overnight.
Tetramethoxysilane (TMOS) is hydrolyzed in aqueous solution to give silicic
acid. The initial chemistry of the coating process is shown below [134].
A summary of the process is shown in 4.5
The silica shell has pores allowing the small molecules to pass through.
However, the payload cannot exit the holes because it is sealed within the particle.
There are many variations of this fabrication approach for different applications.
For instance, PLGA size, lactic-to-glycolic-acid ratio, payload, silica coating time,
and probe sonication duration and power can all potentially be modified.
4.3 Structural Characterization of SiLGA
The nanoparticles size and charge were characterized using scanning elec-
tron microscopy (SEM) and dynamic light scattering (DLS). In order to visually
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Figure 4.5: Step by step synthesis of SiLGA.
confirm that PLGA is coated with Silica, samples were imaged using SEM before
and after coating (figure 4.6). As it can bee seen, there is a clear visual indication
of Silica coating on the PLGA nanoparticles before [fig 4.6A and fig 4.6B] and after
[fig 4.6C and fig 4.6D] the coating process.
Our SEM results indicate a size range of 100 nm - 200 nm for the PLGA nanopar-
ticles and 100nm - 260 nm for SiLGA nanoparticles (figure 4.7).
For further confirmation of Silica coating, size and surface charge of the
nanoparticles were compared before and after the coating process using DLS.
PLGA nanoparticles show a size range of 201.9 nm with a polydispersity index
(PDI) of 0.093, while SiLGA nanoparticles show a size range of 386.7 nm with a
PDI of 0.239.
As it can be seen in 4.8,the DLS data confirms a substantial difference
between the size and charge of the nanoparticles before and after Silica coating.
This should be taken as an additional sign of successful coating. A range of low
PDI values indicates that both PLGA and SiLGA nanoparticles are well-dispersed
in the solution.
We believe that the discrepancy in size between SEM measurements and
DLS data is due to hydrodynamic radius surrounding the charged particle surfaces
and the incomplete removal of the emulsifiers used during synthesis.
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Figure 4.6: SEM images of nanoparticles. A and B) PLGA before coating with
Silica. C and D) PLGA after coating with Silica (SiLGA)
This data, along with the SEM images, clearly shows the correct pattern of
change in the characteristic of PLGA nanoparticles before and after Silica coating.
4.4 Functional Characterization of SiLGA
After successfully characterizing the structural changes due to coating PLGA
with Silica (SiLGA), enzyme activity assays were used to verify enzyme loading
and activity post-encapsulation and coating.
Penicillinase (BLA) was chosen as a mock enzyme to test activity, as well
55
Figure 4.7: PLGA and SiLGA nanoparticles size via SEM
as SiLGA’s protection efficiency against protease enzymes, in vitro.
Penicillinase from Bacillus cereus is a member of the family of beta-lactamases,
which catalyze the hydrolysis of the beta-lactam ring [135].
Unencapsulated (BLA), BLA encapsulated in PLGA (BLA-PLGA), BLA
encapsulated in SiLGA (BLA-SiLGA) were separately incubated with Proteinase
-K (PK). Proteinase K is a serine protease that will cleave any free enzyme not
encapsulated within the nanoparticles or on the particle surfaces.
Remaining activity post PK treatment indicates activity from enzymes pro-
tected from PK exposure from within the nanoparticle’s interior.
The samples were incubated with PK at a final concentration of 0.1 mg/ml
of PK at 370C in a shaking incubator (300 rpm) overnight. In controls (samples
without PK), PK was replaced with 1XPBS. Using nitrocefin as a substrate, an
enzyme activity assay was performed on the samples after incubation at 370C.
Nitrocefin is a chromogenic Îš-lactamase substrate that changes color from yellow
(λmax = 390 nm at pH 7.0) to red (λmax = 486 nm at pH 7.0) as the amide bond
in the Beta-lactam ring is hydrolyzed by BLA.
Each reaction was 100 µl in total volume and contained 250 ug/ml nitrocefin
as substrate; absorbance was measured at 486 nm.
The results can be seen in 4.9 As expected, it can be seen, the unencapsu-
lated BLA loses all its activity when exposed to PK. BLA-PLGA retains only %4
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Figure 4.8: Size and Zeta Potential measurement of PLGA and SiLGA via DLS.
Figure 4.9: BLA activity at 370C as A) Unencapsulated BLA incubated with
or without PK B) BLA encapsulated in PLGA (BLA-PLGA) incubated with or
without PK. C) BLA encapsulated in SiLGA (BLA-SiLGA) incubated with or
without PK.
of its activity of its activity while BLA-SiLGA retains more than %83 of its activity
before and after incubation with PK. We believe that activity loss in BLA-PLGA
is from the burst release of BLA followed by polymer degradation and subsequent
PK access to the enzyme. while such loss is not seen with the SiLGA nanoparticles
due to the protection offered by the Silica coating
This substantial protection of enzymatic activity by SiLGA against PK in
vitro demonstrates the potential effectiveness of SiLGA against proteolysis of the
cargo (enzyme) in vivo.
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4.5 In vivo Tissue Residence time of SiLGA
To asses the residence time of SiLGA in tissue, Alexa fluor 680 conjugated
to Bovine Serum Albumin (BSA) was loaded into SiLGA nanoparticles. Athymic,
nude mice were purchased from the Jackson Laboratories (Stock : 002019). Mice
were housed in high-efficiency particulate air (HEPA) cages in a specific-pathogen
free (SPF) facility at OHSU. Mice were fed a diet of PicoLab Mouse Diet 20
(LabDiet, 5058) ad libitum and started one week prior to imaging. 10 week old male
nude mice were given a single 100µl intramuscular injection of either BSA loaded
SiLGA in the left hind leg muscle or free BSA in the right hind leg muscle. Mice
were imaged for fluorescence (excitation wavelength = 680nm, emission wavelength
= 710nm, exposure = 0.2sec) after correcting for background fluorescence using
the IVIS Lumina XRMS Series III (PerkinElmer). All experiments performed
were approved by the Institutional Animal Care and Use Committee (IACUC) at
OHSU. As it can be seen in figure 4.10 while the unencapsulated BSA is almost
gone in 2 days, the BSA-SiLGA nanoparticles are localized in the tissue for at least
60 days.
Figure 4.10: In vivo tissue residence time of BSA encapsulated in SiLGA compared
to unencapsulated BSA
Residence time is important for many applications including applications
in amino acid depletion and enzyme pro-drug therapy using SiLGA nanoparti-
cles. The promising results of this experiment clearly indicates SiLGA’s stability,
minimal toxicity and biocompatibility, as well as its superior tissue residence time
compared to free BSA.
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4.6 Discussion
To conclude this chapter, we have successfully encapsulated enzymes and
proteins in Silica-coated PLGA nanoparticles (SiLGA) as demonstrated by struc-
tural and functional characterization both in vitro and in vivo.
Our method allows for the entrapment of proteins and enzymes without modi-
fying the enzyme or protein itself. We have shown that adding a porous silica
coating does not reduce enzymatic activity. The porous silica layer of the SiLGA
nanoparticles is too small for the enzyme to escape and for big molecules, like
antibodies and proteolytic enzymes, to reach the enzyme; however, these pores are
sufficiently large to allow substrates to reach the enzyme and for the reaction prod-
uct to diffuse out. The structural characterization confirmed differences in size and
charge between PLGA nanoparticles and SiLGA nanoparticles. PLGA nanopar-
ticles show a size range of 100-200 nm with a polydispersity index of 0.093, while
SiLGA nanoparticles show a size range of 100-260 nm with a PDI of 0.239.The
particles were visually confirmed using SEM.
In the functional characterization, Penicilinase (BLA) was loaded into PLGA
nanoparticles (BLA-PLGA) and then coated with Silica (BLA-SiLGA). We were
able to confirm retention of enzymatic activity throughout the synthesis process.
To confirm superior protection capabilities of SiLGA and successful silica coating,
particles were incubated with a serine protease (Proteinase K) at 370C for 24 hours
where unencapsulated BLA and BLA-PLGA lost almost all of their activity while
BLA-SiLGA retained %83 of its original activity. These strong in vitro results,
in addition to our structural characterization results, give us confidence that sil-
ica coating has been successful and that SiLGA nanoparticles can offer significant
protection against proteolytic enzymes in vivo.
To confirm tissue residence time of SiLGA nanoparticles in vivo, our results
confirms that unencapsulated Alexa fluor-BSA vanishes within one day while Alexa
fluor-BSA encapsulated in SiLGA persists for at least 60 days.
Small particle size combined with inert, FDA-approved materials used in
synthesis will ease the way for clinical translation of these drug delivery vehicles.
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Furthermore, different polymers may be used in this method (e.g. PLA,PMMA,
etc) and different coatings can be applied to the polymer surfaces (e.g. calcium
phosphate, titanium oxide, etc).
The next chapter will address some preliminary applications of SiLGA us-
ing different enzymes.
4.7 Methods
4.7.1 SiLGA Synthesis
The PLGA nanoparticles are made by double emulsion solvent evaporation
method by [122] with minor modification. First an appropriate ratio of enzyme
to Rat Serum Albumin (RSA) (for example: 22mg:8mg or 8mg:22mg ) are made
in 300 µl of water. This makes the initial water phase (W1). RSA protects the
enzyme during the encapsulation process.
The oil phase (O1) consists of 81 mg of PLGA (Poly lactic-co-Glycolic
Acid) and 3mg DMT (Dimethyl L-tartrate) in 3mL of dichloromethane (DCM).
Here DCM is used as the organic solvent and DMT as a plasticizer.
The second water phase (W2) contains a solution of %5 PVA. To prepare
the %5 PVA, first 100 mL of water was heated up to 80C on a hotplate. Then 5 g
of PVA was slowly added while mixing water. Then, the solution was let to reach
room temperature and vacuum filtered. PVA acts as an emulsifier.
The W1 mixture (enzyme and RSA in water) was added drop-wise to the
oil phase (O1:PLGA and DMT in DCM) while vortex mixing for one minute.
Afterwards, this mixture was probe sonicated on ice for 2 minutes with a total
energy output of approximately 1400 Joules.
The mixture was then added drop-wise to 18ml of %5 PVA (polyvinyl al-
cohol) in water, vortex mixed for one minute, and probe sonicated on ice for 2
minutes with a final energy output of approximately 2800 Joules; this process
yielded the second water phase (W2).This makes the W1/O/W2 solution.
The solution was then left stirring overnight at room temperature to re-
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move the organic solvent. This was followed by one hour of stirring in a vacuum
desiccator to completely remove the organic solvent while also allowing the PLGA
nanoparticles to harden.
To wash away excess PVA and any unencapsulated enzyme, the nanoparti-
cles were centrifuged and recovered three times using ultra centrifugation (32000
rpm for 30 minutes at 4C). After each wash, the nanoparticles were resuspended
in water and probe sonicated on ice as mentioned before.
The nanoparticles were then centrifuged at 1500 rpm for 10 minutes, and the
supernatant was recovered. After this step, the synthesis of enzyme encapsulated
PLGA nanoparticles is complete and particles are ready to be coated with Silica.
In empty nanoparticles, enzyme is replaced with RSA.
In order to coat the nanoparticles with silica, 50 µl of PLGA nanoparticles
are added to 1ml of 1XPBS while mixing. A solution of silicic acid is made by
adding 74µl of Tetramethoxysilane (TMOS) to 500µl 1mM HCl. The solution is
mixed for a minute. TMOS is hydrolyzed in aqueous solution to give silicic acid.
Then 15 µl of silicic acid is added drop wise to the particle solution.The resulting
solution is left mixing at 40C over night.
To remove the excess silica, the solution is centrifuged at 4000 rpm for 15
minutes in 40C. The nanoparticles are resuspended in 1XPBS at each step. The
final solution is probe sonicated on ice for 30 seconds (%20 amplitude, 2 seconds
ON / 1 second OFF).
The resulting nanoparticles from this step are enzyme-loaded, Silica-coated
PLGA nanoparticles (enzyme-SiLGA).
Samples are characterized using SEM and DLS as well as enzyme activity
assays for each corresponding enzymes.
4.7.2 Characterization
Absorbance and fluorescence measurements for activity assays were taken
with the TECAN Spark(R) 20M Te-cool(TM). The Helios Nanolab(TM) 660 scan-
ning electron microscope produced micrographs of particles. Particle size, Zeta po-
tential, and polydispersity index were measured using the Malvern Zetasizer Nano
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ZSP dynamic light scattering instrument.
4.7.3 Beta Lactamase Activity Assay
For the colorimetric determination of Beta Lactamse activity, 100 µl of
enzyme solutions were transferred onto a 96-well plate. To obtain the working
solution One milligram nitrocefin was dissolved in 100 µl DMSO, and 1.9 mL 1X
PBS was added.
25 µl of the working solution was added to each well and absorbance at 492 nm
was measured at 370C on a Tecan Spark 10M.
4.7.4 Amplex Red Assay
The Amplex Red Assay Kit (A22180) was used from Invitrogen. Amplex
Red reagent reacts with a 1:1 stoichometry with any unreacted H2O2 in the pres-
ence of horseradish peroxidase (HRP) to produce the highly fluorescent oxidation
product, resorufin.Resorufin has absorption and fluorescence emission maxima of
approximately 571 nm and 585 nm, respectively.
4.7.5 Materials
The following materials were purchased from Sigma Aldrich and used as
received: amorphous PLGA ("Resomer(R) RG 504 H"; acid terminated; lactide(38
kDA):glycolide(54 kDa); monomer ratio of 1:1); lyophilized powder form of peni-
cillinase ("Penicillinase from Bacillus cereus"; 1,500 to 3,000 units per milligram
of protein); lyophilized powder form of rat serum albumin (>99 percent purity);
dimethyl-L-tartarate; dichloromethane (anhydrous; 40 to 150 ppm amylene stabi-
lizer; >99.5 percent purity); polyvinyl alcohol (87 to 90 percent hydrolized; average
molecular weight: 30 to 70 kDa). The presterilized Stericup and Steritop Vacuum
Driven Disposable Filtration System was utilized to filter the %5 PVA aqueous
solution. The Q500 Ultrasonic Processor from QSonica (output: 500 W, 20 kHz)
was used to create the water-oil-water double emulsion.
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Chapter 5
SiLGA Application
5.1 Applications of SiLGA
SiLGA’s exceptional localization in tissue, as well as its minimal toxicity,
holds great promise for exploring its in vivo applications for therapeutic and di-
agnostics purposes. SiLGA’s application in enzyme prodrug therapy as well as
its characterization for antioxidant therapy has been investigated in this chapter.
It is important to bare in mind that SiLGA is a new delivery platform, thus its
application is not just limited to cancer therapy or diagnosis. SiLGA nanoparti-
cles can have many different application in other diseases. For instance it can be
used as an enzyme replacement therapy platform for patients with Phenylketonuria
(PKU) a metabolic genetic disease where phenylalanine, an essential amino acid,
is accumulated in the body and can result in mental retardation. The enzyme,
Phenylalanine ammonia lyase can be used to degrade phenylalanine and has been
shown promising results in the clinic [136]. SiLGA can be loaded with antioxidant
enzymes like catalase and superoxide dismutase for antioxidant therapy and have
been shown to protect neurons against oxidative stress [122], this can be utilized
in diseases such as cerebral ischemia and multiple sclerosis [137, 122]. Catalase
loaded nanoparticles could also be used as a diagnostic tool for in vivo detection
of acute kidney injury (AKI) [138].
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5.1.1 Enzyme Prodrug Therapy
The treatment of solid or metastatic tumors could benefit from enzyme-
prodrug therapies using foreign enzymes that convert a non-cytotoxic prodrug
into its toxic forms at the tumor site by a highly specific localized enzymatic
reaction [11, 139, 140, 18, 141, 142]. Enzyme-prodrug therapy involves the systemic
administration of an inactivated non toxic form of a drug ( prodrug), which can be
converted in the the active form of the drug by an exogenous enzyme. The chosen
exogenous enzyme should either be of foreign origin or have none or very low
endogenous expression. The prodrug needs to be non toxic in its inactivated form
and not be a substrate to endogenous enzymes that would lead to its unspecific
activation in non target tissues [139].
As the limitation of administration of free enzymes have been described
in previous chapters, in enzyme prodrug therapy those issues will be even more
devastating resulting in non specific activation of the prodrug throughout the body.
Thus one of the best ways to circumvent these issues, is to encapsulate the enzyme
in nanoparticles, where the exogenous enzyme intended for the enzyme prodrug
therapy will be encapsulated in a nanoparticle and localized within the target,
followed by systemic administration of the prodrug that is the specific substrate
for the encapsulated enzyme. This will result in local activation of the drug in
the tumor. [139]. With the promising in vivo data obtained with SiLGA, we
hypothesize SiLGA will be an excellent candidate as an enzyme delivery vehicle
for applications in enzyme prodrug therapy (Figure 5.1).
5.1.2 Enzyme Prodrug Therapy Using HRP loaded SiLGA
and IAA
Indoleacetic acid (IAA), is a plant hormone found in most plants. In hu-
mans IAA is a breakdown product of tryptophan metabolism and is often produced
by the action of bacteria in the mammalian gut. Some endogenous production of
IAA in mammalian tissues has also been seen [143]. IAA has been detected in
the central nervous system, urine and blood plasma of humans [144, 145, 146,
147, 148]. Thus IAA is well tolerated in humans [144, 149]. However while IAA
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Figure 5.1: Enzyme prodrug therapy via nanoparticles. First enzyme loaded
nanoparticles will be injected and localized, then the prodrug ( inactivated and
non toxic form of the drug) will be systemically injected, and activated to its
cytotoxic form at the tumor site by the enzymes loaded in the nanoparticles.
is not oxidized by mammalian peroxidases [144], it can be converted to reactive
radicals by horseradish peroxidase (HRP) (figure 5.2 [150].)and be cytotoxic to
cells [151, 152]. HRP is found in the roots of horseradish and is a very robust
heme-containing peroxidase and can oxidize a wide variety of substrates includ-
ing IAA in the presence of hydrogen peroxide. IAA is only toxic after oxidative
decarboxylation; the effect of IAA/HRP is thought to be due in part to the for-
mation of methylene-oxindole, which may conjugate with DNA bases and protein
thiols [153]. The IAA/HRP-mediated apoptotic pathway induces caspase-8 and
caspase-9 activation, which results in caspase-3 activation and poly(ADP-ribose)
polymerase (PARP) cleavage [151].
Neither IAA nor HRP by themselves show cytotoxicity to cells [154, 155].
The robust nature of HRP and the low toxicity of IAA makes the combination of
IAA and HRP an excellent candidate for targeted enzyme prodrug therapy [152,
154, 17, 144, 156, 157]. HRP has previously been conjugated to PEG [158, 159]in-
creasing the molecular weight of the protein by approximately 25 kDa. However
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Figure 5.2: Free radicals formed by oxidation of indole-3-acetic acid by horseradish
peroxidase (HRP) [150].
with this conjugation %50 of the enzymatic activity was lost [157]. Moreover Ad-
ministration of HRP-PEG to tumour-bearing animals indicates a problem of liver
uptake. [157, 160].
There is a clear need for a better and non toxic delivery platform for HRP
without compromising enzymatic efficiency. This can be achieved by encapsula-
tion of HRP in nanoparticles and accumulation of the said nanoparticles in the
tumor followed by systemic administration of IAA that would lead to the localized
activation of the prodrug at the tumour, preventing normal tissue damage.
5.1.3 HRP loaded SiLGA Activity and Dosing
HRP encapsulated SiLGA (HRP-SiLGA) was synthesized as mentioned be-
fore. Horse Radish Peroxidase (HRP) was encapsulated in PLGA and SiLGA.
Empty PLGA and SiLGA particles were made as controls. In controls, enzyme
was replaced with rat serum albumin (RSA).
To evaluate whether the encapsulation process had effected the functionality
of the enzyme, unencapsulated and encapsulated HRP activity was evaluated using
the Amplex Red assay kit.
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As it can be seen in 5.3 HRP encapsulated in PLGA (HRP-PLGA) and
HRP encapsulated in SiLGA (HRP-SiLGA) have maintained enzymatic activity
which confirms the preservation of enzymatic activity after each step of encapsu-
lation.
Figure 5.3: HRP activity compared
As expected, the activity varies as different concentrations of HRP-SiLGA
are used in a dose dependent manner as shown in 5.4
5.1.4 HRP SiLGA Cytotoxcity
Two different concentrations of HRP-SilGA,5.6E9 (HRP-SiLGA-a) and 2.8E11
(HRP-SiLGA-b) , were incubated with HeLa cells for 5 hours. In the positive con-
trol cells, HRP-SiLGA was replaced with 1XPBS. In the negative control, cells
were incubated with triton X and imaged using a confocal microscope. As it can
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Figure 5.4: HRP-SiLGA Dose
be seen in 5.5, the cells incubated both doses HRP-SiLGA and control cells have
similar characteristics to the control, indicating that HRP-SiLGA has minimal
toxicity in HeLa cells, even in higher doses.
5.1.5 HRP-SiLGA and IAA Cell Viability via MTT
As a preliminary investigation for the application of HRP-SiLGA in enzyme
prodrug therapy using IAA, MTT cell viability assay was performed in HeLa cells in
the presence of IAA. HeLa cells were incubated with 0.8 mM IAA alone and 0.8mM
IAA in combination with 5.6E9 HRP-SiLGA nanoparticles for 24 hours. After 24
hours MTT viability assay was performed. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) is a small molecule that is positively charged and
undergoes NADPH-mediated conversion in live cells to form Formazan, changing
its color from blue to purple in live cells that can be detected using a spectropho-
tometer. As it can be seen in 5.6, while 0.8mM of IAA shows no toxicity to the
HeLa cells, the combination of IAA incubated with 5.6E9 HRP-SiLGA nanoparti-
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Figure 5.5: HRP-SiLGA’s toxicity to HeLa cells. HRP-SilGA,5.6E9 (HRP-SiLGA-
a) and 2.8E11 (HRP-SiLGA-b) , were incubated with HeLa cells for 5 hours. In
the positive control cells, HRP-SiLGA was replaced with 1XPBS. In the negative
control, cells were incubated with triton X. Cells were imaged using a confocal
microscope.
cles were able to kill more than %94 of the cells.
5.1.6 Conclusion and Future Direction
Our preliminary experiment with enzyme prodrug therapy using HRP and
IAA has shown promising results. While we have previously shown SiLGA high
tissue residence time and minimal toxicity in mice, our results suggest minimal
toxicity when SiLGA is incubated with HeLA cells. Our results also confirms that
while the dose of IAA was not toxic to cell, its combination with IAA was able
to kill more than %94 of the HeLA cells. These are of course preliminary results
and more dosing studies and time studies are needed for HRP-SiLGA, as well as
IAA in different cell lines. The effects of HRP-SiLGA and IAA can be further
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Figure 5.6: Cell viability analysis using MTT. HeLa cells were incubated with 0.8
mM IAA alone and 0.8mM IAA in combination with HRP-SiLGA nanoparticles for
24 hours. MTT viability assay was performed. Samples were done in triplicates,
error bars as shown.
investigated by tumor shrinking studies in vivo.
5.2 Catalase and Antioxidant Therapy
In our bodies, Reactive Oxygen Species (ROS) such as superoxide anion,
OH (hydroxyl radical) and H2O2 (hydrogen peroxide) are formed as a natural
byproduct of the normal metabolism of oxygen and have important roles in cell
signaling and homeostasis [161] These free radicals have one or more unpaired
electrons, making them highly unstable. During normal conditions in our bodies
there is a balance between the formation of reactive oxygen species and their
clearance. However under certain conditions, this balance can be disrupted and
lead to oxidative stress. Oxidative stress can be seen in in or as a results of many
different conditions such as ischemia and reperfusion in stroke and heart attacks,
cancer, multiple sclerosis, Parkinson’s disease, etc [137, 122, 162, 163, 161].
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To battle ROS, cells make a variety of antioxidant enzymes to convert reac-
tive oxygen species to unharmful substances. Two important players are SuperOx-
ide Dismutase (SOD), which converts super-oxide radicals into hydrogen peroxide,
and catalase (CAT), which converts hydrogen peroxide into water and oxygen gas.
Recent studies have utilized delivery platforms for antioxidant therapy via catalase
[122, 164, 165].
As mentioned before,in an attempt to protect neurons from oxidative stress,
[122] reported successful encapsulation and release of Catalase from PLGA nanopar-
ticles. Catalase is encapsulated in PLGA nanoparticles using double emulsion
solvent evaporation method. These nanoparticles released Catalase activity for a
month in vitro. Although successful encapsulation of Catalase in PLGA nanopar-
ticles was shown, the release mechanism of PLGA nanoparticles remains the same.
Due to the nature of the polymers, the cargo will be burst-released in vivo.
5.2.1 Catalase Loaded SiLGA Synthesis and Activity
In the first step of synthesis, the PLGA nanoparticles are used as a step-
ping stone to encapsulation of catalase using double emulsion solvent evaporation
method [122] (CAT-PLGA) and afterwards the whole nanoparticle is sealed with
a porous silica layer (CAT-SiLGA). This delivery platform,allows for catalaseto be
protected inside the nanoparticles from immune clearance, while small molecules
like hydrogen peroxide can diffuse inside the nanoparticle from the pores of silica
and get converted to unharmful water and oxygen.
Zeta potential charge and poly dispersity index (PDI) was measured using
Dynamic Light Scattering (DLS). PLGA nanoparticles and Silica coated PLGA
nanoparticles (SiLGA) were imaged using Scanning Electron Microscopy (SEM) (
figure 5.7).
After successful syhtnesis and characterization of CAT-SiLGA, enzymatic
activity was measured using the amplex red assay kit. CAT-SiLGA’s activity was
measured to be 125 U/ml per 2.8E11 particles. As it can be seen in 5.8, the silica
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Figure 5.7: SEM images of nanoparticles. Catalase loaded PLGA (CAT-PLGA)
before coating with Silica (left) and Catalase loaded PLGA after coating with Silica
(SiLGA) (right). Bottomn table shows hydrodynamic size, zeta potential charge
and polydispersity index as measured by dynamic light scattering
coating process does not effect catalase activity.
5.2.2 Conclusion and Future Direction
CAT-SiLGA nanoparticles have been successfully synthesized and charac-
terized with high activity. CAT-SiLGA can be utilized in antioxidant therapies
against ischemia and reperfusion injury, cancer, diabetes, Parkinson’s or any dis-
ease or condition that can benefit from antioxidant therapy. CAT-SiLGA can also
be used as a diagnostic tool using ultrasound for detection of regional oxidative
stress [138].
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Figure 5.8: CAT-SiLGA and CAT-PLGA activity showing preservation of enzy-
matic activity throughout the sealing process.
5.3 Methods
5.3.1 Catalase and HRP Loaded SiLGA Synthesis
The PLGA nanoparticles are made by double emulsion solvent evaporation
method by [122] with minor modification. First an appropriate ratio of enzyme
to Rat Serum Albumin (RSA) (for example: 22mg:8mg or 8mg:22mg ) are made
in 300 µl of water. This makes the initial water phase (W1). RSA protects the
enzyme during the encapsulation process.
The oil phase (O1) consists of 81 mg of PLGA (Poly lactic-co-Glycolic
Acid) and 3mg DMT (Dimethyl L-tartrate) in 3mL of dichloromethane (DCM).
Here DCM is used as the organic solvent and DMT as a plasticizer.
The second water phase (W2) contains a solution of %5 PVA. To prepare
the %5 PVA, first 100 mL of water was heated up to 80C on a hotplate. Then 5 g
of PVA was slowly added while mixing water. Then, the solution was let to reach
room temperature and vacuum filtered. PVA acts as an emulsifier
The W1 mixture (enzyme and RSA in water) was added drop-wise to the
oil phase (O1:PLGA and DMT in DCM) while vortex mixing for one minute.
Afterwards, this mixture was probe sonicated on ice for 2 minutes with a total
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energy output of approximately 1400 Joules.
The mixture was then added drop-wise to 18ml of %5 PVA (polyvinyl al-
cohol) in water, vortex mixed for one minute, and probe sonicated on ice for 2
minutes with a final energy output of approximately 2800 Joules; this process
yielded the second water phase (W2). This makes the W1/O/W2 solution.
The solution was then left stirring overnight at room temperature to re-
move the organic solvent. This was followed by one hour of stirring in a vacuum
desiccator to completely remove the organic solvent while also allowing the PLGA
nanoparticles to harden.
To wash away excess PVA and any unencapsulated enzyme, the nanoparti-
cles were centrifuged and recovered three times using ultra centrifugation (32000
rpm for 30 minutes at 4C). After each wash, the nanoparticles were resuspended
in water and probe sonicated on ice as mentioned before.
The nanoparticles were then centrifuged at 1500 rpm for 10 minutes, and the
supernatant was recovered. After this step, the synthesis of enzyme encapsulated
PLGA nanoparticles is complete and particles are ready to be coated with Silica.
In empty nanoparticles, enzyme is replaced with RSA.
In order to coat the nanoparticles with silica, 50 µl of PLGA nanoparticles
are added to 1ml of 1XPBS while mixing. A solution of silicic acid is made by
adding 74µl of Tetramethoxysilane (TMOS) to 500µl 1mM HCl. The solution is
mixed for a minute. TMOS is hydrolyzed in aqueous solution to give silicic acid.
Then 15 µl of silicic acid is added drop wise to the particle solution.The resulting
solution is left mixing at 40C over night.
To remove the excess silica, the solution is centrifuged at 4000 rpm for 15
minutes in 40C. The nanoparticles are resuspended in 1XPBS at each step. The
final solution is probe sonicated on ice for 30 seconds (%20 amplitude, 2 seconds
ON / 1 second OFF). The resulting nanoparticles from this step are enzyme-loaded,
Silica-coated PLGA nanoparticles (enzyme-SiLGA).
Samples are characterized using SEM and DLS as well as enzyme activity
assays for each corresponding enzymes
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5.3.2 Amplex Red Assay
The Amplex Red Assay Kit (A22180) was used from Invitrogen. Amplex
Red reagent reacts with a 1:1 stoichometry with any unreacted H2O2 in the pres-
ence of horseradish peroxidase (HRP), or HRP-SiLGA to produce the highly flu-
orescent oxidation product, resorufin. Resorufin has absorption and fluorescence
emission maxima of approximately 571 nm and 585 nm, respectively.
5.3.3 Cell Culture
HeLa (ATCC CCL-2) cells was used to test toxicity of HRP-SiLGA . The
cells were sub cultured at least 4 times prior to the study. 5000 cells/ well were
plated and incubated 24 hours. The treatments were only studied upon 60-70%
con fluency each well. The cells were incubated with 14E10 (high concentration of
HRP-SiLGA) and 56E8 (low concentration of HRP-SiLGA). In the control HRP-
SiLGA was replaced with PBS. Cells were imaged using a microscope.
5.3.4 Cell Viability via MTT Assay
HeLa (ATCC CCL-2) cells were used to test toxicity and these cells were
sub cultured at least 4 times prior to the study.5000 cells/ well were plated and
incubated 24 hours prior to any treatment. The treatments were only studied
upon 60-70% con fluency each well. The cells were incubated with 0.8mM IAA
and 1.4E11 HRP-SiLGA+0.8 mM IAA for 24 hours. In the controls IAA or HRP-
SiLGA was replaced with PBS. Before the addition of the MTT reagent, the media
was removed and replaced with the media containing 0.2mM MTT. The cells were
incubated at 370C incubator for 3 hours before the addition of 50µl of DMSO to
determine the absorbance at 540nm. All samples were done in triplicates.
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5.3.5 Characterization
Absorbance and fluorescence measurements for activity assays were taken
with the TECAN Spark(R) 20M Te-cool(TM). The Helios Nanolab(TM) 660 scan-
ning electron microscope produced micrographs of particles. Particle size, Zeta po-
tential, and polydispersity index were measured using the Malvern Zetasizer Nano
ZSP dynamic light scattering instrument.
5.4 Material
The following materials were purchased from Sigma Aldrich and used as
received: amorphous PLGA ("Resomer(R) RG 504 H"; acid terminated; lactide(38
kDA):glycolide(54 kDa); monomer ratio of 1:1); MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-Diphenyltetrazolium Bromide) Thermo Fisher Scientific M6494; Pierce
Horseradish Peroxidase from Thermo Fisher Scientific; Catalase from bovine liver,
lyophilized powder, 2,000-5,000 units/mg protein from Sigma-Aldrich. lyophilized
powder form of rat serum albumin (>99 percent purity); dimethyl-L-tartarate;
dichloromethane (anhydrous; 40 to 150 ppm amylene stabilizer; >99.5 percent
purity); polyvinyl alcohol (87 to 90 percent hydrolized; average molecular weight:
30 to 70 kDa). Molecular Probes Amplex Red Catalase Assay Kit from Fisher.The
presterilized Stericup and Steritop Vacuum Driven Disposable Filtration System
was utilized to filter the %5 PVA aqueous solution. The Q500 Ultrasonic Processor
from QSonica (output: 500 W, 20 kHz) was used to create the water-oil-water
double emulsion.
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Chapter 6
Conclusion and Future Potentials
In this dissertation, two types of silica nanoparticles are discussed as efficient
and robust enzyme delivery platforms. The porous silica coating on the surface
of these nanoparticles allow them to operate like a nano-shark cages: the encap-
sulated enzyme (the scuba diver) is too large to diffuse out from the nanoparticle
interior, antibodies (the sharks) are too big to reach the enzyme by diffusing into
the nanoparticle interior, and small molecules like substrates or reaction products
(the small fish) can freely diffuse in and out of the nanoparticles. The nano-shark
cage-like effect of these nanoparticles demonstrate great advantage over conven-
tional enzyme therapies, where the recombinant enzyme is rapidly cleared from the
body due to its foreign nature and current enzyme delivery technologies (e.g. di-
rect modification of the enzyme with PEG) which prompts some loss of enzymatic
activity and only partially protects the enzyme from immune clearance.
The first nanoparticle system discussed are Synthetic Hollow Enzyme-Loaded
Silica nanospheres (SHELS). SHELS were utilized for the depletion of the amino
acid methionine using the enzyme, methioninase, via methioninase-loaded SHELS
(MethSHELS). The experimental results for methSHELS showed successful encap-
sulation of Methioninase. MethSHELS maintained more than %60 of their activity
after exposure to protease enzymes (proteinase K). One of the greatest challenges
associated with Methioninase is cofactor loss, which leads to enzyme inactivation in
the presence albumin, the most abundant blood protein. Our experimental results
showed that methioninase encapsulation in SHELS improves the enzymatic stabil-
78
79
ity by preventing inactivation in the presence of human serum albumin. Moreover,
a more durable and deeper methionine depletion was seen by MethSHELS com-
pared to bare (unencapsulated) Methioninase for up to 12 hours when injected
intramuscularly. Future directions include :acquiring higher quality Methioninase
to be loaded into the SHELS as well as further optimization of loading and dosing
of MethSHELS, specifically for in vivo studies.
Even though SHELS show promise as a delivery platform, they entail a
complicated synthesis process. Due to size limitations of the holes, enzyme loading,
especially for bigger or slightly aggregated enzymes, will be challenging. This issue
increases in magnitude as the particle size decreases; we anticipate pore size to
limit 100 nm SHELS spheres notably more than 200 nm SHELS spheres. Even so,
the two-step synthesis of SHMS and SHELS both involve silica and utilizing an
FDA-approved material already common in the clinic has clear benefits.
With that in mind, a new delivery platform was developed using FDA-
approved poly(lactic-co-glycolic acid) (PLGA). PLGA was used as a scaffold to
encapsulate different enzymes and was coated with a porous silica layer to over-
come the greatest challenge of PLGA nanoparticles: the burst release of their cargo.
For this purpose, silica-coated enzyme-loaded PLGA nanoparticles (SiLGA) were
developed and their structural, in-vitro functional, and in-vivo tissue residence
time were characterized. Structural characterization results confirmed differences
in size and charge between PLGA nanoparticles and SiLGA nanoparticles.PLGA
nanoparticles had an average size range of 100-200 nm with a polydispersity index
of 0.093, while SiLGA nanoparticles showed a size range of 100-260 nm with a
PDI of 0.239. The particles were also visually characterized using SEM to confirm
successful silica coating. For functional characterization, Penicilinase (BLA) was
loaded into PLGA nanoparticles (BLA-PLGA) and then coated with Silica (BLA-
SiLGA). BLA-SiLGA maintained of enzymatic activity throughout the synthesis
process, exhibiting more than %83 of the BLA activity upon exposure to the pro-
tease enzyme, proteinase K. This shows a clear advantage over the %64 retention of
activity previously achieved by SHELS and the %4 retention of activity by PLGA
alone. Strong in vitro results further confirm successful silica coating. The superior
protection capabilities of enzyme-loaded SiLGA nanoparticles gives us more con-
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fidence that SiLGA nanoparticles offer significant and similar protection against
proteolytic enzymes in vivo. To explore in vivo behavior, Alexafluor680-conjugated
BSA was encapsulated in SiLGA (BSA-SiLGA) and injected intramuscularly into
mice. While unencapsulated BSA cleared within a day, the BSA-SiLGA was non-
toxic to mice and show an in-tissue-residence time at least 60 days when they are
injected intramuscularly. Repeated dosing, quantification of immune response, and
alternative routes of in vivo administration require further study.
SiLGA’s application was investigated in enzyme prodrug therapy using
Horseradish Peroxidase (HRP)-loaded SiLGA (HRP-SiLGA). Indoleacetic acid
(IAA), a non-toxic plant hormone used as a non-active prodrug, can be systemi-
cally injected and activated at the tumor site by localized HRP-SiLGA to produce
free radicals toxic to cancer cells. For this purpose, HRP-SiLGA was developed
and characterized in vitro. While we have previously shown high tissue retention
time of SiLGA nanoparticles with minimal toxicity in mice, our preliminary results
also show that HRP-SiLGA has minimal toxicity to HeLa cells. Moreover, our pre-
liminary MTT results showed high cytotoxicty to HeLA cells (%>94) when HRP-
SiLGA was combined with IAA, but minimal cytotoxicity for IAA alone. These
preliminary results are quite promising. Further optimization of HRP-SiLGA, as
well as more detailed dosing studies, could greatly improve these results. The
effects of HRP-SiLGA and IAA will be further investigated by tumor-shrinking
studies in vivo. Catalase-loaded SiLGA (CAT-SiLGA) was also developed as a po-
tential antioxidant therapeutic and diagnostic. CAT-SiLGA was successfully syn-
thesized and characterized, demonstrating high activity. These promising results
makes CAT-SiLGA a promising delivery platform for application in antioxidant
therapies against ischemia and reperfusion injury, cancer, diabetes, Parkinson’s,
and any disease or condition that can benefit from antioxidant therapy. Used in-
conjunction with ultrasound, CAT-SiLGA can also serve as a diagnostic system
for detecting regions of oxidative stress.
SiLGA nanoparticles are a novel nanoscale delivery platform and can be
employed in therapeutic and diagnostic applications in different diseases.The inert
nature of their constituent, FDA-approved materials as well as their small size
and mechanism of action, makes SiLGA practical and effective for enzyme deliv-
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ery in many diseases and conditions including cancer (for amino acid depletion
therapy and enzyme prodrug therapy), antioxidant therapy for oxidative stress
for example in ischemia and reperfusion injury, Multiple Sclerosis,Diabetes,etc, as
well as enzyme replacement therapy for genetic diseases. SiLGA nanoparticles
could potentially be used for imaging by encapsulating a fluorescent payload or as
bio-sensors. Additionally, the silica surfaces of these particles can be modified to
enhance circulation and targeting in vivo without modifying the payload itself.
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